

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number  
**WO 01/00244 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 47/48**

(21) International Application Number: PCT/US00/17229

(22) International Filing Date: 23 June 2000 (23.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/141,316 25 June 1999 (25.06.1999) US  
60/189,844 16 March 2000 (16.03.2000) US

(71) Applicant (*for all designated States except US*): GENENTECH, INC. [US/US]: 1 DNA Way, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ERICKSON, Sharon [US/US]: 970 Vista Road, Hillsborough, CA 94010 (US). SCHWALL, Ralph [US/US]: 400 Griffen Avenue, Pacifica, CA 94044 (US).

(74) Agent: ALTMAN, Daniel, E.: Knobbe, Martens, Olson and Bear, LLP, 16th Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES

(57) Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.

WO 01/00244 A2

## METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES

Background of the InventionField of the Invention

5 The present invention concerns methods of treatment, especially ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods.

Description of the Related Art1. Maytansine and maytansinoids

10 Maytansine was first isolated from the east African shrub *Maytenus serrata* (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinol and maytansinol analogues are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 15 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, the disclosures of which are hereby expressly incorporated by reference.

Maytansine and maytansinoids are highly cytotoxic but their clinical use in cancer therapy has been greatly limited by their severe systemic side-effects primarily attributed to their poor selectivity for tumors. Clinical trials with maytansine had been discontinued due to serious adverse effects on the central nervous system and 20 gastrointestinal system (Issel *et al.*, *Can. Trtmnt. Rev.* 5:199-207 [1978]).

2. The ErbB family of receptor tyrosine kinases and anti-ErbB antibodies

Members of the ErbB family of receptor tyrosine kinases are important mediators of cell growth, differentiation and survival. The receptor family includes four distinct members, including epidermal growth factor receptor (EGFR or ErbB1), HER2 (ErbB2 or p185<sup>neu</sup>), HER3 (ErbB3) and HER4 (ErbB4 or tyro2). 25 p185<sup>neu</sup>, was originally identified as the product of the transforming gene from neuroblastomas of chemically treated rats. The activated form of the *neu* proto-oncogene results from a point mutation (valine to glutamic acid) in the transmembrane region of the encoded protein. Amplification of the human homolog of *neu* is observed in breast and ovarian cancers and correlates with a poor prognosis (Slamon *et al.*, *Science*, 235:177-182 (1987); Slamon *et al.*, *Science*, 244:707-712 (1989); and US Pat No. 4,968,603). To date, no point mutation analogous to that in the *neu* 30 proto-oncogene has been reported for human tumors. Overexpression of ErbB2 (frequently but not uniformly due to gene amplification) has also been observed in other carcinomas including carcinomas of the stomach, endometrium, salivary gland, lung, kidney, colon, thyroid, pancreas and bladder. See, among others, King *et al.*, *Science*, 229:974 (1985); Yokota *et al.*, *Lancet*: 1:765-767 (1986); Fukushima *et al.*, *Mol Cell Biol.*, 6:955-958 (1986); Geurin *et al.*, *Oncogene Res.*, 3:21-31 (1988); Cohen *et al.*, *Oncogene*, 4:81-88 (1989); Yonemura *et al.*, *Cancer Res.*, 51:1034 35 (1991); Borst *et al.*, *Gynecol. Oncol.*, 38:364 (1990); Weiner *et al.*, *Cancer Res.*, 50:421-425 (1990); Kern *et al.*,

*Cancer Res.*, 50:5184 (1990); Park *et al.*, *Cancer Res.*, 49:6605 (1989); Zhau *et al.*, *Mol. Carcinog.*, 3:354-357 (1990); Aasland *et al. Br. J. Cancer* 57:358-363 (1988); Williams *et al. Pathobiology* 59:46-52 (1991); and McCann *et al.*, *Cancer*, 65:88-92 (1990). ErbB2 may be overexpressed in prostate cancer (Gu *et al. Cancer Lett.* 99:185-9 (1996); Ross *et al. Hum. Pathol.* 28:827-33 (1997); Ross *et al. Cancer* 79:2162-70 (1997); and Sadasivan *et al. J. Urol.* 150:126-31 (1993)). A spliced form of erbB2 oncogen encoding a constitutively tyrosine phosphorylated ErbB2 receptor is disclosed in PCT publication WO 00/20579, published on April 13, 2000. The erbB2 protein encoded by the splice variant has an in frame deletion of 16 amino acids (CVDLDDKGCPAEQRAS), two of which are conserved cysteine residues.

Antibodies directed against the rat p185<sup>neu</sup> and human ErbB2 protein products have been described. Drebin and colleagues have raised antibodies against the rat *neu* gene product, p185<sup>neu</sup>. See, for example, Drebin *et al.*, *Cell* 41:695-706 (1985); Myers *et al.*, *Meth. Enzym.* 198:277-290 (1991); and WO94/22478. Drebin *et al. Oncogene* 2:273-277 (1988) report that mixtures of antibodies reactive with two distinct regions of p185<sup>neu</sup> result in synergistic anti-tumor effects on *neu*-transformed NIH-3T3 cells implanted into nude mice. See also U.S. Patent 5,824,311 issued October 20, 1998.

Other anti-ErbB2 antibodies with various properties have been described in Tagliabue *et al. Int. J. Cancer* 47:933-937 (1991); McKenzie *et al. Oncogene* 4:543-548 (1989); Maier *et al. Cancer Res.* 51:5361-5369 (1991); Bacus *et al. Molecular Carcinogenesis* 3:350-362 (1990); Stancovski *et al. PNAS (USA)* 88:8691-8695 (1991); Bacus *et al. Cancer Research* 52:2580-2589 (1992); Xu *et al. Int. J. Cancer* 53:401-408 (1993); WO94/00136; Kasprzyk *et al. Cancer Research* 52:2771-2776 (1992); Hancock *et al. Cancer Res.* 51:4575-4580 (1991); Shawver *et al. Cancer Res.* 54:1367-1373 (1994); Arteaga *et al. Cancer Res.* 54:3758-3765 (1994); Harwerth *et al. J. Biol. Chem.* 267:15160-15167 (1992); U.S. Patent No. 5,783,186; and Klapper *et al. Oncogene* 14:2099-2109 (1997).

Hudziak *et al.*, *Mol. Cell. Biol.* 9(3): 1165-1172 (1989) describe the generation of a panel of anti-ErbB2 antibodies which were characterized using the human breast tumor cell line SK-BR-3. Relative cell proliferation of the SK-BR-3 cells following exposure to the antibodies was determined by crystal violet staining of the monolayers after 72 hours. Using this assay, maximum inhibition was obtained with the antibody called 4D5 which inhibited cellular proliferation by 56%. Other antibodies in the panel reduced cellular proliferation to a lesser extent in this assay. The antibody 4D5 was further found to sensitize ErbB2-overexpressing breast tumor cell lines to the cytotoxic effects of TNF-. See also U.S. Patent No. 5,677,171 issued October 14, 1997. The anti-ErbB2 antibodies discussed in Hudziak *et al.* are further characterized in Fendly *et al. Cancer Research* 50:1550-1558 (1990); Kotts *et al. In Vitro* 26(3):59A (1990); Sarup *et al. Growth Regulation* 1:72-82 (1991); Shepard *et al. J. Clin. Immunol.* 11(3):117-127 (1991); Kumar *et al. Mol. Cell. Biol.* 11(2):979-986 (1991); Lewis *et al. Cancer Immunol. Immunother.* 37:255-263 (1993); Pietras *et al. Oncogene* 9:1829-1838 (1994); Vitetta *et al. Cancer Research* 54:5301-5309 (1994); Sliwkowski *et al. J. Biol. Chem.* 269(20):14661-14665 (1994); Scott *et al. J. Biol. Chem.* 266:14300-5 (1991); D'souza *et al. Proc. Natl. Acad. Sci.* 91:7202-7206 (1994); Lewis *et al. Cancer Research* 56:1457-1465 (1996); and Schaefer *et al. Oncogene* 15:1385-1394 (1997).

The murine monoclonal anti-HER2 antibody inhibits the growth of breast cancer cell lines that overexpress HER2 at the 2+ and 3+ level, but has no activity on cells that express lower levels of HER2 (Lewis *et al.*, *Cancer Immunol. Immunother.* [1993]). Based on this observation, antibody 4D5 was humanized (Carter *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 4285-4289 [1992]). The humanized version designated HERCEPTIN® (huMAb4D5-8, rhuMAb  
5 HER2, U.S. Patent No. 5,821,337) was tested in breast cancer patients whose tumors overexpress HER2 but who had progressed after conventional chemotherapy (Baselga *et al.*, *J. Clin. Oncol.* 14:737-744 [1996]); Cobleigh *et al.*, *J. Clin. Oncol.* 17: 2639-2648 [1999]). Most patients in this trial expressed HER2 at the 3+ level, though a fraction was 2+ tumors. Remarkably, HERCEPTIN® induced clinical responses in 15% of patients (complete responses in 4% of patients, and partial responses in 11%) and the median duration of those responses was 9.1 months. HERCEPTIN®  
10 received marketing approval from the Food and Drug Administration September 25, 1998 for the treatment of patients with metastatic breast cancer whose tumors overexpress the ErbB2 protein.

Homology screening has resulted in the identification of two other ErbB receptor family members; ErbB3 (US Pat. Nos. 5,183,884 and 5,480,968 as well as Kraus *et al.* *PNAS (USA)* 86:9193-9197 (1989)) and ErbB4 (EP Pat Appln No 599,274; Plowman *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:1746-1750 (1993); and Plowman *et al.*, *Nature*,  
15 366:473-475 (1993)). Both of these receptors display increased expression on at least some breast cancer cell lines.

### 3. Maytansinoid-antibody conjugates

In an attempt to improve their therapeutic index, maytansine and maytansinoids have been conjugated to antibodies specifically binding to tumor cell antigens. Immunoconjugates containing maytansinoids are disclosed, for example, in U.S. Patent Nos. 5,208,020; 5,416,064 and European Patent EP 0 425 235 B1, the disclosures of which  
20 are hereby expressly incorporated by reference. Liu *et al.*, *Proc. Natl. Acad. Sci. USA* 93:8618-8623 (1996) described immunoconjugates comprising a maytansinoid designated DM1 linked to the monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic towards cultured colon cancer cells, and showed antitumor activity in an *in vivo* tumor growth assay. Chari *et al.* *Cancer Research* 52:127-131 (1992) describe immunoconjugates in which a maytansinoid was conjugated via a disulfide linker to the murine antibody A7  
25 binding to an antigen on human colon cancer cell lines, or to another murine monoclonal antibody TA.1 that binds the HER-2/*neu* oncogene. The cytotoxicity of the TA.1-maytansinoid conjugate was tested *in vitro* on the human breast cancer cell line SK-BR-3, which expresses  $3 \times 10^5$  HER-2 surface antigens per cell. The drug conjugate achieved a degree of cytotoxicity similar to the free maytansinoid drug, which could be increased by increasing the number of maytansinoid molecules per antibody molecule. The A7-maytansinoid conjugate showed low systemic cytotoxicity in  
30 mice.

Although HERCEPTIN® is a breakthrough in treating patients with ErbB2-overexpressing breast cancers that have received extensive prior anti-cancer therapy, generally approximately 85% of the patients in this population fail to respond, or respond only poorly, to HERCEPTIN® treatment, and in the clinical trial preceding marketing approval, the median time to disease progression in all treated patients was only 3.1 months. Therefore, there is a significant  
35 clinical need for developing further HER2-directed cancer therapies for those patients with HER2-overexpressing

tumors or other diseases associated with HER2 expression that do not respond, or respond poorly, to HERCEPTIN<sup>®</sup> treatment.

#### Summary of the Invention

5           The present invention is based on the unexpected experimental finding that HERCEPTIN<sup>®</sup>-maytansinoid conjugates are highly effective in the treatment of HER2 (ErbB2) overexpressing tumors that do not respond, or respond poorly, to HERCEPTIN<sup>®</sup> therapy.

10           In one aspect, the present invention concerns a method for the treatment of a tumor in a mammal, wherein the tumor is characterized by the overexpression of an ErbB receptor and does not respond or responds poorly to treatment with a monoclonal anti-ErbB antibody, comprising administering to the mammal a therapeutically effective amount of a conjugate of the anti-ErbB antibody with a maytansinoid.

15           In a preferred embodiment, the patient is human. In another preferred embodiment, the ErbB receptor is (human) ErbB2 (HER2). The method is not limited by the mechanism of action of the anti-ErbB antibody used. Thus, the anti-ErbB antibody may, for example, have growth inhibitory properties and/or may induce cell death and/or apoptosis. In a particularly preferred embodiment, the method concerns the treatment of cancer including, without limitation, breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate and bladder cancer. Preferably the cancer is breast cancer, in particular, breast cancer which overexpresses ErbB2 at a 2+ level or above, more preferably at a 3+ level. A preferred group of antibodies has a biological characteristic of

20           a 4D5 monoclonal antibody, or binds essentially the same epitope as a 4D5 monoclonal antibody, a humanized form of the murine monoclonal antibody 4D5 (ATCC CRL 10463) being particularly preferred.

25           The maytansinoid used in the conjugates of the present invention may be maytansine or, preferably, maytansinol or a maytansinol ester. The antibody and maytansinoid may be conjugated by a bispecific chemical linker, such as N-succinimidyl-4-(2-pyridylthio)propanoate (SPDP) or N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP). The linking group between the antibody and the maytansinoid may, for example, be a disulfide, thioether, acid labile, photolabile, peptidase labile, or esterase labile group.

30           In another aspect, the invention concerns an article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an anti-ErbB antibody-maytansinoid conjugate, and further comprising a package insert or label indicating that the composition can be used to treat cancer characterized by overexpression of an ErbB receptor, preferably at a 2+ level or above.

#### Brief Description of the Drawings

Figure 1 shows the structure of the maytansinoid, designated "DM1."

Figure 2 illustrates the structure of a HERCEPTIN<sup>®</sup>-DM1 conjugate.

35           Figure 3 is the elution profile of HERCEPTIN<sup>®</sup>-DM1 conjugate on a Sephacryl S300 gel filtration column.

Figure 4 shows the nucleotide sequence of a HER2 transgene plasmid construct (SEQ ID NO: 1) directing the expression of native human HER2 (ErbB2) in the mammary gland of a transgenic mouse. The figure includes the nucleotide sequence of HER2 (ErbB2) cDNA insert (SEQ ID NO: 2) as well as the deduced amino acid sequence of HER2 (ErbB2) (SEQ ID NO: 3), including the signal sequence. Within SEQ ID NO: 3, residues from about 22 to about 645, inclusive represent the HER2 (ErbB2) extracellular domain.

Figure 5 illustrates the effect of HERCEPTIN<sup>®</sup>-DM1 on HER2-transgenic tumors. Two mm<sup>3</sup> pieces of MMTV-HER2-transgenic tumors were transplanted into the mammary fat pad of FVB mice. When tumors reached 250 mm<sup>3</sup>, groups of 8 mice were injected i.v. on 5 consecutive days with a HERCEPTIN<sup>®</sup>-DM1 conjugate. Two other groups of mice were treated IP twice per week with 10 mg/kg of either HERCEPTIN<sup>®</sup> or RITUXAN<sup>®</sup>.

Figure 6 shows the heavy chain variable region sequence of a humanized anti-HER2 antibody 2C4.

Figure 7 shows the light chain variable region sequence of a humanized anti-HER2 antibody 2C4.

#### Detailed Description of the Invention

##### 1. Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.*, *Dictionary of Microbiology and Molecular Biology 2nd ed.*, J. Wiley & Sons (New York, NY 1994). One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

An "ErbB receptor" or "ErbB" is a receptor protein tyrosine kinase which belongs to the ErbB receptor family and includes ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4) receptors and other members of this family to be identified in the future. The definition specifically includes ErbB receptors encoded by spliced forms of the corresponding erbB oncogenes, including, without limitation, the deletion variant of ErbB2 disclosed in PCT publication No. WO 00/20579 (published on April 13, 2000). The ErbB receptor will generally comprise an extracellular domain, which may bind an ErbB ligand; a lipophilic transmembrane domain; a conserved intracellular tyrosine kinase domain; and a carboxyl-terminal signaling domain harboring several tyrosine residues which can be phosphorylated. The ErbB receptor may be a "native sequence" ErbB receptor or a functional derivative, such as an "amino acid sequence variant" thereof. Preferably the ErbB receptor is native sequence human ErbB receptor.

The terms "ErbB1", "epidermal growth factor receptor" and "EGFR" are used interchangeably herein and refer to native sequence EGFR as disclosed, for example, in Carpenter *et al. Ann. Rev. Biochem.* 56:881-914 (1987), including naturally occurring mutant forms thereof (*e.g.* a deletion mutant EGFR as in Humphrey *et al. PNAS (USA)* 87:4207-4211 (1990)), and its functional derivatives, such as amino acid sequence variants. *erbB1* refers to the gene encoding the EGFR protein product.

The expressions "ErbB2" and "HER2" are used interchangeably herein and refer to native sequence human HER2 protein described, for example, in Semba *et al., PNAS (USA)* 82:6497-6501 (1985) and Yamamoto *et al. Nature*

319:230-234 (1986) (Genebank accession number X03363), and functional derivatives, such as amino acid sequence variants thereof. The term *erbB2* refers to the gene encoding human HER2 and *neu* refers to the gene encoding rat p185<sup>neu</sup>. Preferred HER2 is native sequence human HER2. Examples of antibodies which bind HER2 include MAbs 4D5 (ATCC CRL 10463), 2C4 (ATCC HB-12697), 7F3 (ATCC HB-12216), and 7C2 (ATCC HB 12215) (see, US Patent No. 5,772,997; WO98/77797; and US Patent No. 5,840,525, expressly incorporated herein by reference). Humanized anti-HER2 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN®) as described in Table 3 of U.S. Patent 5,821,337 expressly incorporated herein by reference; humanized 520C9 (WO93/21319). Human anti-HER2 antibodies are described in U.S. Patent No. 5,772,997 issued June 30, 1998 and WO 97/00271 published January 3, 1997.

"ErbB3" and "HER3" refer to the receptor polypeptide as disclosed, for example, in US Pat. Nos. 5,183,884 and 5,480,968 as well as Kraus *et al.* *PNAS (USA)* 86:9193-9197 (1989), and functional derivatives, including amino acid sequence variants thereof. Examples of antibodies which bind HER3 are described in US Patent No. 5,968,511 (Akita and Sliwkowski), *e.g.* the 8B8 antibody (ATCC HB 12070) or a humanized variant thereof.

The terms "ErbB4" and "HER4" herein refer to the receptor polypeptide as disclosed, for example, in EP Pat Appln No 599,274; Plowman *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:1746-1750 (1993); and Plowman *et al.*, *Nature*, 366:473-475 (1993), and functional derivatives, including amino acid sequence variants thereof such as the HER4 isoforms disclosed in WO 99/19488.

A "native" or "native sequence" EGFR, HER2, HER3 or HER4 polypeptide may be isolated from nature, produced by techniques of recombinant DNA technology, chemically synthesized, or produced by any combinations of these or similar methods.

"Functional derivatives" include amino acid sequence variants, and covalent derivatives of the native polypeptides as long as they retain a qualitative biological activity of the corresponding native polypeptide. Amino acid sequence variants generally differ from a native sequence in the substitution, deletion and/or insertion of one or more amino acids anywhere within a native amino acid sequence. Deletional variants include fragments of the native polypeptides, and variants having N- and/or C-terminal truncations. Ordinarily, amino acid sequence variants will possess at least about 70% homology, preferably at least about 80%, more preferably at least about 90% homology with a native polypeptide.

"Homology" is defined as the percentage of residues in the amino acid sequence variant that are identical after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Methods and computer programs for the alignment are well known in the art. One such computer program is "Align 2", authored by Genentech, Inc., which was filed with user documentation in the United States Copyright Office, Washington, DC 20559, on December 10, 1991.

By "ErbB ligand" is meant a polypeptide which binds to and/or activates an ErbB receptor. The ErbB ligand of particular interest herein is a native sequence human ErbB ligand such as Epidermal Growth Factor (EGF) (Savage *et al.*, *J. Biol. Chem.* 247:7612-7621 (1972)); Transforming Growth Factor alpha (TGF-alpha) (Marquardt *et al.*, *Science*

223:1079-1082 (1984)); amphiregulin also known as schwanoma or keratinocyte autocrine growth factor (Shoyab *et al. Science* 243:1074-1076 (1989); Kimura *et al. Nature* 348:257-260 (1990); and Cook *et al. Mol. Cell. Biol.* 11:2547-2557 (1991)); betacellulin (Shing *et al., Science* 259:1604-1607 (1993); and Sasada *et al. Biochem. Biophys. Res. Commun.* 190:1173 (1993)); heparin-binding epidermal growth factor (HB-EGF) (Higashiyama *et al., Science* 251:936-939 (1991)); epiregulin (Toyoda *et al., J. Biol. Chem.* 270:7495-7500 (1995); and Komurasaki *et al. Oncogene* 15:2841-2848 (1997)), a heregulin (see below); neuregulin-2 (NRG-2) (Carraway *et al., Nature* 387:512-516 (1997)); neuregulin-3 (NRG-3) (Zhang *et al., Proc. Natl. Acad. Sci.* 94:9562-9567 (1997)); or cripto (CR-1) (Kannan *et al. J. Biol. Chem.* 272(6):3330-3335 (1997)). ErbB ligands which bind EGFR include EGF, TGF- $\alpha$ , amphiregulin, betacellulin, HB-EGF and epiregulin. ErbB ligands which bind HER3 include heregulins. ErbB ligands capable of binding HER4 include betacellulin, epiregulin, HB-EGF, NRG-2, NRG-3 and heregulins.

"Heregulin" (HRG) when used herein refers to a polypeptide which activates the ErbB2-ErbB3 and ErbB2-ErbB4 protein complexes (i.e. induces phosphorylation of tyrosine residues in the complex upon binding thereto). Various heregulin polypeptides encompassed by this term are disclosed in Holmes *et al., Science* 256:1205-1210 (1992); WO 92/20798; Wen *et al., Mol. Cell. Biol.* 14(3):1909-1919 (1994) and Marchionni *et al., Nature* 362:312-318 (1993), for example. The term includes biologically active fragments and/or variants of a naturally occurring HRG polypeptide, such as an EGF-like domain fragment thereof (e.g. HRG $\beta_{177-244}$ ).

An "ErbB hetero-oligomer" herein is a noncovalently associated oligomer comprising at least two different ErbB receptors. Such complexes may form when a cell expressing two or more ErbB receptors is exposed to an ErbB ligand and can be isolated by immunoprecipitation and analyzed by SDS-PAGE as described in Sliwkowski *et al., J. Biol. Chem.*, 269(20):14661-14665 (1994), for example. Examples of such ErbB hetero-oligomers include EGFR-HER2, HER2-HER3 and HER3-HER4 complexes. Moreover, the ErbB hetero-oligomer may comprise two or more HER2 receptors combined with a different ErbB receptor, such as HER3, HER4 or EGFR. Other proteins, such as a cytokine receptor subunit (e.g. gp130), may be included in the hetero-oligomer.

In the context of HER2 variants, such as HER2 fragments, the phrase "having the biological activity of a native human HER2" is used to refer to the qualitative ability of such fragments to induce tumor growth when overexpressed in an animal model (transgenic or non-transgenic) of the present invention.

"Tumor", as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g. epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer,



colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.

5 A cancer which "overexpresses" an ErbB receptor is one which has significantly higher levels of an ErbB receptor, such as HER2, at the cell surface thereof, compared to a noncancerous cell of the same tissue type. Such overexpression may be caused by gene amplification or by increased transcription or translation. ErbB receptor overexpression may be determined in a diagnostic or prognostic assay by evaluating increased levels of the ErbB protein present on the surface of a cell (*e.g.* via an immunohistochemistry assay; IHC). Alternatively, or additionally, one may measure levels of ErbB-encoding nucleic acid in the cell, *e.g.* via fluorescent *in situ* hybridization (FISH; see  
10 WO98/45479 published October, 1998), Southern blotting, or polymerase chain reaction (PCR) techniques, such as real time quantitative PCR (RT-PCR). One may also study ErbB receptor overexpression by measuring shed antigen (*e.g.*, ErbB extracellular domain) in a biological fluid such as serum (see, *e.g.*, U.S. Patent No. 4,933,294 issued June 12, 1990; WO91/05264 published April 18, 1991; U.S. Patent 5,401,638 issued March 28, 1995; and Sias *et al. J. Immunol. Methods* 132: 73-80 (1990)). Aside from the above assays, various *in vivo* assays are available to the  
15 skilled practitioner. For example, one may expose cells within the body of the patient to an antibody which is optionally labeled with a detectable label, *e.g.* a radioactive isotope, and binding of the antibody to cells in the patient can be evaluated, *e.g.* by external scanning for radioactivity or by analyzing a biopsy taken from a patient previously exposed to the antibody.

The tumors overexpressing HER2 are rated by immunohistochemical scores corresponding to the number of  
20 copies of HER2 molecules expressed per cell, and can be determined biochemically: 0 = 0-10,000 copies/cell, 1+ = at least about 200,000 copies/cell, 2+ = at least about 500,000 copies/cell, 3+ = at least about 2,000,000 copies/cell. Overexpression of HER2 at the 3+ level, which leads to ligand-independent activation of the tyrosine kinase (Hudziak *et al., Proc. Natl. Acad. Sci. USA* 84: 7159-7163 (1987)), occurs in approximately 30% of breast cancers, and in these patients, relapse-free survival and overall survival are diminished (Slamon *et al., Science* 244:  
25 707-712 (1989); Slamon *et al., Science* 235: 177-182 (1987)).

Conversely, a cancer which is "not characterized by overexpression of an ErbB receptor" is one which, in a diagnostic assay, does not express higher than normal levels of ErbB receptor compared to a noncancerous cell of the same tissue type.

A "hormone independent" cancer is one in which proliferation thereof is not dependent on the presence of a  
30 hormone which binds to a receptor expressed by cells in the cancer. Such cancers do not undergo clinical regression upon administration of pharmacological or surgical strategies that reduce the hormone concentration in or near the tumor. Examples of hormone independent cancers include androgen independent prostate cancer, estrogen independent breast cancer, endometrial cancer and ovarian cancer. Such cancers may begin as hormone dependent tumors and progress from a hormone-sensitive stage to a hormone-refractory tumor following anti-hormonal therapy.

The term "antibody" herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (*e.g.* bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler *et al.*, *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (see, *e.g.*, U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson *et al.*, *Nature*, 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991), for example.

The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)). Chimeric antibodies of interest herein include primatized antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (*e.g.* Old World Monkey, Ape etc) and human constant region sequences.

"Antibody fragments" comprise a portion of an intact antibody, preferably comprising the antigen-binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragment(s).

An "intact" antibody is one which comprises an antigen-binding variable region as well as a light chain constant domain (C<sub>L</sub>) and heavy chain constant domains, C<sub>H</sub>1, C<sub>H</sub>2 and C<sub>H</sub>3. The constant domains may be native sequence constant domains (*e.g.* human native sequence constant domains) or amino acid sequence variant thereof. Preferably, the intact antibody has one or more effector functions.

"Humanized" forms of non-human (*e.g.*, rodent) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman

primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones *et al.*, *Nature* 321:522-525 (1986); Riechmann *et al.*, *Nature* 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992).

Humanized anti-ErbB2 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN<sup>®</sup>) as described in Table 3 of U.S. Patent 5,821,337 expressly incorporated herein by reference; humanized 520C9 (WO93/21319) and humanized 2C4 antibodies as those shown in Figure 6.

Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (*e.g.* B cell receptor; BCR), etc.

Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different "classes". There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into "subclasses" (isotypes), *e.g.*, IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called , , , and , respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

"Antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to a cell-mediated reaction in which nonspecific cytotoxic cells that express Fc receptors (FcRs) (*e.g.* Natural Killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. The primary cells for mediating ADCC, NK cells, express Fc RIII only, whereas monocytes express Fc RI, Fc RII and Fc RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, *Annu. Rev. Immunol* 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an *in vitro* ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, *e.g.*, in a animal model such as that disclosed in Clynes *et al. PNAS (USA)* 95:652-656 (1998).

"Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least Fc RIII and perform ADCC effector function. Examples of human leukocytes

which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source thereof, *e.g.* from blood or PBMCs as described herein.

The terms "Fc receptor" or "FcR" are used to describe a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc RI, Fc RII, and Fc RIII subclasses, including allelic variants and alternatively spliced forms of these receptors. Fc RII receptors include Fc RIIA (an "activating receptor") and Fc RIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor Fc RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor Fc RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (see review M. in Daëron, *Annu. Rev. Immunol.* 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-92 (1991); Capel *et al.*, *Immunomethods* 4:25-34 (1994); and de Haas *et al.*, *J. Lab. Clin. Med.* 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer *et al.*, *J. Immunol.* 117:587 (1976) and Kim *et al.*, *J. Immunol.* 24:249 (1994)).

"Complement dependent cytotoxicity" or "CDC" refers to the ability of a molecule to lyse a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (*e.g.* an antibody) complexed with a cognate antigen. To assess complement activation, a CDC assay, *e.g.* as described in Gazzano-Santoro *et al.*, *J. Immunol. Methods* 202:163 (1996), may be performed.

"Native antibodies" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V<sub>H</sub>) followed by a number of constant domains. Each light chain has a variable domain at one end (V<sub>L</sub>) and a constant domain at its other end. The constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains.

The term "variable", as used in connection with antibodies, refers to the fact that certain portions of the antibody variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the

framework regions (FRs). The variable domains of native heavy and light chains each comprise four FRs, largely adopting a  $\beta$ -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the  $\beta$ -sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).

The term "hypervariable region" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (*e.g.* residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (*e.g.* residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk *J. Mol. Biol.* 196:901-917 (1987)). "Framework Region" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.

An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody *in situ* within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

An antibody "which binds" an antigen of interest, *e.g.* ErbB2 antigen, is one capable of binding that antigen with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting a cell expressing the antigen and/or for targeted delivery of a cytotoxic or other chemotherapeutic agent, such as a maytansinoid. Where the antibody is one which binds ErbB2, it will usually preferentially bind ErbB2 as opposed to other ErbB receptors, and may be one which does not significantly cross-react with other proteins such as EGFR, ErbB3 or ErbB4. In such embodiments, the extent of binding of the antibody to these non-ErbB2 proteins (*e.g.*, cell surface binding to endogenous receptor) will be less than 10% as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA). Sometimes, the anti-ErbB2 antibody will not significantly cross-

react with the rat *neu* protein, *e.g.*, as described in Schecter *et al. Nature* 312:513 (1984) and Drebin *et al., Nature* 312:545-548 (1984).

Unless indicated otherwise, the expressions "monoclonal antibody 4D5", and "4D5 monoclonal antibody" refer to an antibody that has antigen binding residues of, or derived from, the murine 4D5 antibody. For example, the monoclonal antibody 4D5 may be murine monoclonal antibody 4D5 (ATCC CRL 10463) or a variant thereof, such as humanized antibody 4D5, possessing antigen binding amino acid residues of murine monoclonal antibody 4D5. Exemplary humanized 4D5 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN®) as in US Patent No. 5,821,337, with huMAb4D5-8 (HERCEPTIN®) being a preferred humanized 4D5 antibody.

An antibody having a "biological characteristic" of a designated antibody, such as the monoclonal antibody designated 4D5, is one which possesses one or more of the biological characteristics of that antibody which distinguish it from other antibodies that bind to the same antigen (*e.g.* ErbB2). For example, an antibody with a biological characteristic of 4D5 may show growth inhibitory effect on ErbB2 overexpressing cells in a manner that is dependent on the ErbB2 expression level and/or bind the same epitope in the extracellular domain of ErbB2 as that bound by 4D5 (*e.g.* which blocks binding of monoclonal antibody 4D5 to ErbB2).

A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially an ErbB expressing cancer cell either *in vitro* or *in vivo*. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of ErbB expressing cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxanes, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in *The Molecular Basis of Cancer*, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13.

Examples of "growth inhibitory" antibodies are those which bind to ErbB2 and inhibit the growth of cancer cells overexpressing ErbB2. Preferred growth inhibitory anti-ErbB2 antibodies inhibit growth of SK-BR-3 breast tumor cells in cell culture by greater than 20%, and preferably greater than 50% (*e.g.* from about 50% to about 100%) at an antibody concentration of about 0.5 to 30 g/ml, where the growth inhibition is determined six days after exposure of the SK-BR-3 cells to the antibody (see U.S. Patent No. 5,677,171 issued October 14, 1997). The SK-BR-3 cell growth inhibition assay is described in more detail in that patent and hereinbelow. The preferred growth inhibitory antibody is monoclonal antibody 4D5, *e.g.*, humanized 4D5.

A molecule (*e.g.* antibody) which "induces cell death" is one which causes a viable cell to become nonviable. The cell is generally one which expresses the ErbB2 receptor, especially where the cell overexpresses the ErbB2 receptor. Preferably, the cell is a cancer cell, *e.g.* a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney,

colon, thyroid, pancreatic, prostate or bladder cancer cell. *In vitro*, the cell may be a SK-BR-3, BT474, Calu 3, MDA-MB-453, MDA-MB-361 or SKOV3 cell. Cell death *in vitro* may be determined in the absence of complement and immune effector cells to distinguish cell death induced by antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). Thus, the assay for cell death may be performed using heat inactivated serum (*i.e.* in the absence of complement) and in the absence of immune effector cells. To determine whether the molecule is able to induce cell death, loss of membrane integrity as evaluated by uptake of propidium iodide (PI), trypan blue (see Moore *et al. Cytotechnology* 17:1-11 (1995)) or 7AAD can be assessed relative to untreated cells. Preferred cell death-inducing antibodies are those which induce PI uptake in the PI uptake assay in BT474 cells. Examples of antibodies which induce cell death include anti-ErbB2 antibodies 7C2 and 7F3 (WO 98/17797, expressly incorporated herein by reference), including humanized and/or affinity matured variants thereof.

A molecule (e.g. antibody) which "induces apoptosis" is one which induces programmed cell death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). The cell is usually one which overexpresses the ErbB2 receptor. Preferably the cell is a tumor cell, *e.g.* a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic, prostate or bladder cancer cell. *In vitro*, the cell may be a SK-BR-3, BT474, Calu 3 cell, MDA-MB-453, MDA-MB-361 or SKOV3 cell. Various methods are available for evaluating the cellular events associated with apoptosis. For example, phosphatidyl serine (PS) translocation can be measured by annexin binding; DNA fragmentation can be evaluated through DNA laddering; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in hypodiploid cells. Preferably, the molecule which induces apoptosis is one which results in about 2 to 50 fold, preferably about 5 to 50 fold, and most preferably about 10 to 50 fold, induction of annexin binding relative to untreated cell in an annexin binding assay using BT474 cells. Sometimes the pro-apoptotic molecule will be one which further blocks ErbB ligand activation of an ErbB receptor. In other situations, the molecule is one which does not significantly block ErbB ligand activation of an ErbB receptor. Further, the molecule may induce apoptosis, without inducing a large reduction in the percent of cells in S phase (*e.g.* one which only induces about 0-10% reduction in the percent of these cells relative to control). Examples of antibodies which induce apoptosis include anti-ErbB2 antibodies 7C2 and 7F3 (WO 98/17797, expressly incorporated herein by reference), including humanized and/or affinity matured variants thereof.

An antibody which "blocks" ligand activation of an ErbB receptor is one which reduces or prevents such activation as hereinabove defined, wherein the antibody is able to block ligand activation of the ErbB receptor substantially more effectively than monoclonal antibody 4D5, *e.g.* about as effectively as monoclonal antibodies 7F3 or 2C4 or Fab fragments thereof and preferably about as effectively as monoclonal antibody 2C4 or a Fab fragment thereof. For example, the antibody that blocks ligand activation of an ErbB receptor may be one which is about 50-100% more effective than 4D5 at blocking formation of an ErbB hetero-oligomer. Blocking of ligand activation of an ErbB receptor can occur by any means, *e.g.* by interfering with: ligand binding to an ErbB receptor, ErbB complex formation, tyrosine kinase activity of an ErbB receptor in an ErbB complex and/or phosphorylation of tyrosine kinase

residue(s) in or by an ErbB receptor. Examples of antibodies which block ligand activation of an ErbB receptor include monoclonal antibodies 2C4 and 7F3 (which block HRG activation of ErbB2/ErbB3 and ErbB2/ErbB4 hetero-oligomers; and EGF, TGF- $\beta$ , amphiregulin, HB-EGF and/or epiregulin activation of an EGFR/ErbB2 hetero-oligomer); and L26, L96 and L288 antibodies (Klapper *et al. Oncogene* 14:2099-2109 (1997)), which block EGF and NDF binding to T47D cells  
5 which express EGFR, ErbB2, ErbB3 and ErbB4. Humanized and/or affinity matured variants these and other antibodies within the definition are specifically included.

The term "epitope" is used to refer to binding sites for (monoclonal or polyclonal) antibodies on protein antigens.

Antibodies that bind to a certain epitope are identified by "epitope mapping." There are many methods  
10 known in the art for mapping and characterizing the location of epitopes on proteins, including solving the crystal structure of an antibody-antigen complex, competition assays, gene fragment expression assays, and synthetic peptide-based assays, as described, for example, in Chapter 11 of Harlow and Lane, *Using Antibodies, a Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999. Competition assays are discussed below. According to the gene fragment expression assays, the open reading frame encoding the protein is  
15 fragmented either randomly or by specific genetic constructions and the reactivity of the expressed fragments of the protein with the antibody to be tested is determined. The gene fragments may, for example, be produced by PCR and then transcribed and translated into protein *in vitro*, in the presence of radioactive amino acids. The binding of the antibody to the radioactively labeled protein fragments is then determined by immunoprecipitation and gel electrophoresis. Certain epitopes can also be identified by using large libraries of random peptide sequences displayed  
20 on the surface of phage particles (phage libraries). Alternatively, a defined library of overlapping peptide fragments can be tested for binding to the test antibody in simple binding assays. The latter approach is suitable to define linear epitopes of about 5 to 15 amino acids.

An antibody binds "essentially the same epitope" as a reference antibody, when the two antibodies recognize identical or sterically overlapping epitopes. The most widely used and rapid methods for determining  
25 whether two epitopes bind to identical or sterically overlapping epitopes are competition assays, which can be configured in all number of different formats, using either labeled antigen or labeled antibody. Usually, the antigen is immobilized on a 96-well plate, and the ability of unlabeled antibodies to block the binding of labeled antibodies is measured using radioactive or enzyme labels.

The "epitope 4D5" is the region in the extracellular domain of ErbB2 to which the antibody 4D5 (ATCC CRL  
30 10463) binds. This epitope is close to the transmembrane domain of ErbB2, and extends from about residue 519 to about residue 625, inclusive within the ErbB2 extracellular domain sequence included in SEQ ID NO: 3, Figure 4. To screen for antibodies which bind to the 4D5 epitope, a routine cross-blocking assay such as that described in Harlow and Lane, *supra*, can be performed. Alternatively, epitope mapping can be performed to assess whether the antibody binds to the 4D5 epitope of ErbB2 (*e.g.* any one or more residues in the region from about residue 529 to about  
35 residue 625, inclusive in SEQ ID NO: 3).



The "epitope 3H4" is the region in the extracellular domain of ErbB2 to which the antibody 3H4 binds. This epitope includes residues from about 541 to about 599, inclusive, in the amino acid sequence of ErbB2 extracellular domain (see Figure 4 and SEQ ID NO: 3).

The "epitope 7C2/7F3" is the region at the N terminus of the extracellular domain of ErbB2 to which the 7C2 and/or 7F3 antibodies (each deposited with the ATCC, see below) bind. To screen for antibodies which bind to the 7C2/7F3 epitope, a routine cross-blocking assay such as that described in *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, epitope mapping can be performed to establish whether the antibody binds to the 7C2/7F3 epitope on ErbB2 (e.g. any one or more of residues in the region from about residue 22 to about residue 53 of ErbB2; see Figure 4, and SEQ ID NO: 3).

A tumor which "does not respond, or responds poorly, to treatment with a monoclonal anti-ErbB antibody" does not show statistically significant improvement in response to anti-ErbB antibody treatment when compared to no treatment or treatment with placebo in a recognized animal model or a human clinical trial, or which responds to initial treatment with anti-ErbB antibodies but grows as treatment is continued. A particularly suitable animal model for testing the efficacy of anti-ErbB antibodies is the transgenic animal model disclosed herein, and illustrated in Example 3.

The terms "treat" or "treatment" refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development or spread of cancer. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

A "disorder" is any condition that would benefit from treatment of the present invention. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include benign and malignant tumors; leukemias and lymphoid malignancies, in particular breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic, prostate or bladder cancer. A preferred disorder to be treated in accordance with the present invention is malignant tumor, such as breast cancer, that overexpresses an ErbB receptor (e.g. ErbB2 and/or EGFR), and does not respond or responds poorly to treatment with antibody to the receptor(s) that is/are overexpressed. A particularly preferred disorder is an ErbB2-overexpressing breast cancer that does not respond or responds poorly to HERCEPTIN<sup>®</sup> therapy.

The term "therapeutically effective amount" refers to an amount of a drug effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number

of cancer cells; reduce the tumor size; inhibit (*i.e.*, slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (*i.e.*, slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (*e.g.* At<sup>211</sup>, I<sup>131</sup>, I<sup>125</sup>, Y<sup>90</sup>, Re<sup>186</sup>, Re<sup>188</sup>, Sm<sup>153</sup>, Bi<sup>212</sup>, P<sup>32</sup> and radioactive isotopes of Lu), chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN™); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabycin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitioctanol, mepitioctane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK ; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2', 2' - trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, *e.g.* paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, NJ) and doxetaxel (TAXOTERE®, Rhône-Poulenc Rorer, Antony, France); chlorambucil;

gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

The term "prodrug" as used in this application refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic to tumor cells compared to the parent drug and is capable of being enzymatically activated or converted into the more active parent form. See, *e.g.*, Wilman, "Prodrugs in Cancer Chemotherapy" *Biochemical Society Transactions*, 14, pp. 375-382, 615th Meeting Belfast (1986) and Stella *et al.*, "Prodrugs: A Chemical Approach to Targeted Drug Delivery," *Directed Drug Delivery*, Borchardt *et al.*, (ed.), pp. 247-267, Humana Press (1985). The prodrugs of this invention include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, -lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted into the more active cytotoxic free drug. Examples of cytotoxic drugs that can be derivatized into a prodrug form for use in this invention include, but are not limited to, those chemotherapeutic agents described above.

The term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term also includes, as equivalents, analogs of either DNA or RNA made from nucleotide analogs, and as applicable, single (sense or antisense) and double-stranded polynucleotides. An "isolated" nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the nucleic acid. An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells. However, an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the antibody where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. The term "expression vector" includes plasmids, cosmids or phages capable of synthesizing the subject HER2 protein encoded by the respective recombinant gene carried by the vector. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. In the

present specification, "plasmid" and "vector" are used interchangeably, as the plasmid is the most commonly used form of vector.

As used herein, the terms "transcriptional regulatory elements" and "transcriptional regulatory sequences" are used interchangeably and refer to nucleic acid, e.g. DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, enhancers, splicing signals and polyadenylation signals. These terms are intended to encompass all elements that promote or regulate transcription, including promoters, core elements required for basic interaction of RNA polymerase and transcription factors, upstream elements, enhancers, and response elements (Lewin, "Genes V" (Oxford University Press, Oxford) pages 847-873). Reference herein to the transcriptional regulatory elements of a gene or class of gene includes both all or an intact region of the naturally occurring transcriptional regulatory elements and modified forms of the transcriptional regulatory elements of the gene or group of genes. Such modified forms include rearrangements of the elements, deletions of some elements or extraneous sequences, and insertion of heterologous elements. The modular nature of transcriptional regulatory elements and the absence of position-dependence of the function of some regulatory elements such as enhancers make such modifications possible. Numerous techniques are available for dissecting the regulatory elements of genes to determine their location and function. Such information can be used to direct modification of the elements, if desired. It is preferred, however, that an intact region of the transcriptional regulatory elements of a gene be used.

The term "tissue-specific promoter" means a nucleotide sequence that serves as a promoter, i.e., regulates expression of a selected DNA sequence operably linked to the promoter, and which effects expression of the selected DNA sequence in specific cells of a tissue, such as cells of a mammary gland. In an illustrative embodiment, gene constructs utilizing mammary gland-specific promoters can be used to preferentially direct expression of a HER2 protein or protein fragment in the mammary gland tissue.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term "transfection" refers to the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell by nucleic acid-mediated gene transfer. "Transformation", as used herein, refers to a process in which a

cell's genotype is changed as a result of the cellular uptake of exogenous DNA or RNA, and, for example, the transformed cell expresses a recombinant form of HER2.

As used herein, the term "transgene" refers to a nucleic acid sequence which is partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the natural gene or its insertion results in a knockout). A transgene can be operably linked to one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that may be necessary for optimal expression of a selected nucleic acid.

Accordingly, the term "transgene construct" refers to a nucleic acid which includes a transgene, and (optionally) such other nucleic acid sequences as transcriptionally regulatory sequence, polyadenylation sites, replication origins, marker genes, etc., which may be useful in the general manipulation of the transgene for insertion in the genome of a host organism.

The term "transgenic" is used herein as an adjective to describe the property, for example, of an animal or a construct, of harboring a transgene. For instance, as used herein, a "transgenic organism" is any animal, preferably a non-human mammal, in which one or more of the cells of the animal contain heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA. In the typical transgenic animals described herein, the transgene causes cells to express or overexpress a recombinant form of the subject HER2 proteins. The terms "founder line" and "founder animal" refer to those animals that are the mature product of the embryos to which the transgene was added, i.e., those animals that grew from the embryos into which DNA was inserted, and that were implanted into one or more surrogate hosts.

The terms "progeny" and "progeny of the transgenic animal" refer to any and all offspring of every generation subsequent to the originally transformed mammals. The term "non-human mammal" refers to all members of the class Mammalia except humans. "Mammal" refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as mouse, rat, rabbit, pig, sheep, goat, cattle and higher primates.

As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have

the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as the anti-ErbB2 antibodies disclosed herein and, optionally, a chemotherapeutic agent) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.

A "cardioprotectant" is a compound or composition which prevents or reduces myocardial dysfunction (*i.e.* cardiomyopathy and/or congestive heart failure) associated with administration of a drug, such as an anti-ErbB antibody or its maytansinoid conjugate, to a patient. The cardioprotectant may, for example, block or reduce a free-radical-mediated cardiotoxic effect and/or prevent or reduce oxidative-stress injury. Examples of cardioprotectants encompassed by the present definition include the iron-chelating agent dexrazoxane (ICRF-187) (Seifert *et al. The Annals of Pharmacotherapy* 28:1063-1072 (1994)); a lipid-lowering agent and/or anti-oxidant such as probucol (Singal *et al. J. Mol. Cell Cardiol.* 27:1055-1063 (1995)); amifostine (aminothiols 2-[(3-aminopropyl)amino]ethanethiol-dihydrogen phosphate ester, also called WR-2721, and the dephosphorylated cellular uptake form thereof called WR-1065) and S-3-(3-methylaminopropylamino)propylphosphorothioic acid (WR-151327), see Green *et al. Cancer Research* 54:738-741 (1994); digoxin (Bristow, M.R. In: Bristow MR, ed. *Drug-Induced Heart Disease*. New York: Elsevier 191-215 (1980)); beta-blockers such as metoprolol (Hjalmarson *et al. Drugs* 47:Suppl 4:31-9 (1994); and Shaddy *et al. Am. Heart J.* 129:197-9 (1995)); vitamin E; ascorbic acid (vitamin C); free radical scavengers such as oleanolic acid, ursolic acid and N-acetylcysteine (NAC); spin trapping compounds such as alpha-phenyl-tert-butyl nitron (PBN); (Paracchini *et al., Anticancer Res.* 13:1607-1612 (1993)); selenoorganic compounds such as P251 (Elbesen); and the like.

## 2. Detailed Description

The present invention is based on results obtained in a novel murine HER2-transgenic tumor model in which HERCEPTIN<sup>®</sup> or the murine antibody 4D5 from which HERCEPTIN<sup>®</sup> was derived, had little effect on tumor growth. Using this model to test the efficacy of HERCEPTIN<sup>®</sup> and HERCEPTIN<sup>®</sup>-maytansinoid conjugates, it was surprisingly found that while the transplanted tumor obtained from such transgenic mice responded poorly to HERCEPTIN<sup>®</sup> treatment, the HERCEPTIN<sup>®</sup>-maytansinoid conjugates were highly efficacious.

Accordingly, the present invention is based on the use of anti-ErbB antibody-maytansinoid conjugates in the treatment of ErbB overexpressing tumors that do not respond well to anti-ErbB antibody and/or maytansinoid treatment.

### A. Production of anti-ErbB antibodies

A description follows as to exemplary techniques for the production of the antibodies used in accordance with the present invention. The production of antibodies will be illustrated with reference to anti-ErbB2 antibodies but it will be apparent for those skilled in the art that antibodies to other members of the ErbB receptor family can be produced and modified in a similar manner.

5 The ErbB2 antigen to be used for production of antibodies may be, *e.g.*, a soluble form of the extracellular domain of ErbB2 or a portion thereof, containing the desired epitope. Alternatively, cells expressing ErbB2 at their cell surface (*e.g.* NIH-3T3 cells transformed to overexpress ErbB2; or a carcinoma cell line such as SK-BR-3 cells, see Stancovski *et al.* *PNAS (USA)* 88:8691-8695 (1991)) can be used to generate antibodies. Other forms of ErbB2 useful for generating antibodies will be apparent to those skilled in the art.

10 (i) *Polyclonal antibodies*

Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, *e.g.*, keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride,  $\text{SOCl}_2$ , or  $\text{R}^1\text{N}=\text{C}=\text{NR}$ , where R and  $\text{R}^1$  are different alkyl groups.

15 Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, *e.g.*, 100 g or 5 g of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

25 (ii) *Monoclonal antibodies*

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.

30 For example, the monoclonal antibodies may be made using the hybridoma method first described by Kohler *et al.*, *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then

are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); and Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson *et al.*, *Anal. Biochem.*, 107:220 (1980).

After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in



bacteria of DNA encoding the antibody include Skerra *et al.*, *Curr. Opinion in Immunol.*, 5:256-262 (1993) and Plückthun, *Immunol. Revs.*, 130:151-188 (1992).

In a further embodiment, monoclonal antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty *et al.*, *Nature*, 348:552-554 (1990). Clackson *et al.*,  
5 *Nature*, 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks *et al.*, *Bio/Technology*, 10:779-783 (1992)), as well as combinatorial infection and *in vivo* recombination as a strategy for constructing very large phage libraries (Waterhouse *et al.*, *Nuc. Acids. Res.*, 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional  
10 monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

The DNA also may be modified, for example, by substituting the coding sequence for human heavy chain and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; and Morrison, *et al.*, *Proc. Natl Acad. Sci. USA*, 81:6851 (1984)), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.

15 Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

(iii) *Humanized antibodies*

20 Methods for humanizing non-human antibodies have been described in the art. Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, *Nature*, 321:522-525 (1986); Riechmann *et al.*, *Nature*, 332:323-327 (1988); Verhoeven *et al.*, *Science*, 239:1534-  
25 1536 (1988)), by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

30 The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework region (FR) for the humanized antibody (Sims *et al.*, *J. Immunol.*, 151:2296 (1993); Chothia *et al.*, *J. Mol. Biol.*, 196:901 (1987)).

35 Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a

particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); Presta *et al.*, *J. Immunol.*, 151:2623 (1993)).

It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, *i.e.*, the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

Example 1 below describes production of an exemplary humanized anti-ErbB2 antibody. The humanized antibody herein may, for example, comprise nonhuman hypervariable region residues incorporated into a human variable heavy domain and may further comprise a framework region (FR) substitution at a position selected from the group consisting of 69H, 71H and 73H utilizing the variable domain numbering system set forth in Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991). In one embodiment, the humanized antibody comprises FR substitutions at two or all of positions 69H, 71H and 73H.

Various forms of the humanized antibody are contemplated. For example, the humanized antibody may be an antibody fragment, such as a Fab. Alternatively, the humanized antibody may be an intact antibody, such as an intact IgG1 antibody.

#### (iv) Human antibodies

As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (*e.g.*, mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region ( $J_H$ ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, *e.g.*, Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:2551 (1993); Jakobovits *et al.*, *Nature*, 362:255-258 (1993); Bruggermann *et al.*, *Year in Immuno.*, 7:33 (1993); and U.S. Patent Nos. 5,591,669, 5,589,369 and 5,545,807.

Alternatively, phage display technology (McCafferty *et al.*, *Nature* 348:552-553 (1990)) can be used to produce human antibodies and antibody fragments *in vitro*, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a

major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats; for their review see, *e.g.*, Johnson, Kevin S. and Chiswell, David J., *Current Opinion in Structural Biology* 3:564-571 (1993). Several sources of V-gene segments can be used for phage display. Clackson *et al.*, *Nature*, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks *et al.*, *J. Mol. Biol.* 222:581-597 (1991), or Griffith *et al.*, *EMBO J.* 12:725-734 (1993). See, also, U.S. Patent Nos. 5,565,332 and 5,573,905.

As discussed above, human antibodies may also be generated by *in vitro* activated B cells (see U.S. Patents 5,567,610 and 5,229,275).

Human anti-ErbB2 antibodies are described in U.S. Patent No. 5,772,997 issued June 30, 1998 and WO 97/00271 published January 3, 1997.

#### (v) Antibody fragments

Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, *e.g.*, Morimoto *et al.*, *Journal of Biochemical and Biophysical Methods* 24:107-117 (1992); and Brennan *et al.*, *Science*, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, the antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from *E. coli* and chemically coupled to form F(ab')<sub>2</sub> fragments (Carter *et al.*, *Bio/Technology* 10:163-167 (1992)). According to another approach, F(ab')<sub>2</sub> fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. The antibody fragment may also be a "linear antibody", *e.g.*, as described in U.S. Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific.

#### (vi) Bispecific antibodies

Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of the ErbB2 protein. Other such antibodies may combine an ErbB2 binding site with binding site(s) for EGFR, ErbB3 and/or ErbB4. Alternatively, an anti-ErbB2 arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (*e.g.* CD2 or CD3), or Fc receptors for IgG (Fc R), such as Fc RI (CD64), Fc RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the ErbB2-expressing cell. Bispecific antibodies may also be used to localize

cytotoxic agents to cells which express ErbB2. WO 96/16673 describes a bispecific anti-ErbB2/anti-Fc RIII antibody and U.S. Patent No. 5,837,234 discloses a bispecific anti-ErbB2/anti-Fc RI antibody. A bispecific anti-ErbB2/Fc antibody is shown in WO98/02463. U.S. Patent No. 5,821,337 teaches a bispecific anti-ErbB2/anti-CD3 antibody.

Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific  
5 antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein *et al.*, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar  
10 procedures are disclosed in WO 93/08829, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991). According to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light chain binding, present in at least one of the  
15 fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at  
20 least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as  
25 the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

According to another approach described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from  
30 recombinant cell culture. The preferred interface comprises at least a part of the C<sub>H</sub>3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (*e.g.* tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (*e.g.* alanine or threonine). This provides a mechanism for increasing the yield of the  
35 heterodimer over other unwanted end-products such as homodimers.

Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, *Science*, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab'-SH fragments from *E. coli*, which can be chemically coupled to form bispecific antibodies. Shalaby *et al.*, *J. Exp. Med.*, 175: 217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny *et al.*, *J. Immunol.*, 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V<sub>H</sub> and V<sub>L</sub> domains of one fragment are forced to pair with the complementary V<sub>L</sub> and V<sub>H</sub> domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber *et al.*, *J. Immunol.*, 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt *et al.* *J. Immunol.* 147: 60 (1991).

(vii) Other amino acid sequence modifications

Amino acid sequence modification(s) of the anti-ErbB2 antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of the anti-ErbB2 antibody are prepared by introducing appropriate nucleotide changes into the anti-ErbB2 antibody nucleic acid, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the anti-ErbB2 antibody.

Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the anti-ErbB2 antibody, such as changing the number or position of glycosylation sites.

A useful method for identification of certain residues or regions of the anti-ErbB2 antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells *Science*, 244:1081-1085 (1989). Here, a residue or group of target residues are identified (*e.g.*, charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with ErbB2 antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed anti-ErbB2 antibody variants are screened for the desired activity.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an anti-ErbB2 antibody with an N-terminal methionyl residue or the antibody fused to a cytotoxic polypeptide. Other insertional variants of the anti-ErbB2 antibody molecule include the fusion to the N- or C-terminus of the anti-ErbB2 antibody to an enzyme (*e.g.* for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the anti-ErbB2 antibody molecule replaced by a different residue. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in Table 1, or as further described below in reference to amino acid classes, may be introduced and the products screened.

Table 1

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; asp, lys; arg	gln
Asp (D)	glu; asn	glu
Cys (C)	ser; ala	ser
Gln (Q)	asn; glu	asn
Glu (E)	asp; gln	asp
Gly (G)	Ala	ala
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe; norleucine	leu
Leu (L)	norleucine; ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala; tyr	tyr
Pro (P)	Ala	ala
Ser (S)	Thr	thr
Thr (T)	Ser	ser
Trp (W)	tyr; phe	tyr
Tyr (Y)	trp; phe; thr; ser	phe

Val (V)	ile; leu; met; phe; ala; norleucine	leu
---------	--	-----

Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

Any cysteine residue not involved in maintaining the proper conformation of the anti-ErbB2 antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

A particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (*e.g.* a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (*e.g.* 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (*e.g.* binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and human ErbB2. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.



It may be desirable to modify the antibody of the invention with respect to effector function, *e.g.* so as to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain  
 5 disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron *et al.*, *J. Exp Med.* 176:1191-1195 (1992) and Shopes, B. *J. Immunol.* 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al. Cancer Research* 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual  
 10 Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson *et al. Anti-Cancer Drug Design* 3:219-230 (1989).

To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (*e.g.*, IgG<sub>1</sub>, IgG<sub>2</sub>,  
 15 IgG<sub>3</sub>, or IgG<sub>4</sub>) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

#### (viii) Glycosylation Variants

Antibodies are glycosylated at conserved positions in their constant regions (Jefferis and Lund, *Chem. Immunol.* 65:111-128 [1997]; Wright and Morrison, *TibTECH* 15:26-32 [1997]). The oligosaccharide side chains of the immunoglobulins affect the protein's function (Boyd *et al.*, *Mol. Immunol.* 32:1311-1318 [1996]; Wittwe and  
 20 Howard, *Biochem.* 29:4175-4180 [1990]), and the intramolecular interaction between portions of the glycoprotein which can affect the conformation and presented three-dimensional surface of the glycoprotein (Hefferis and Lund, *supra*; Wyss and Wagner, *Current Opin. Biotech.* 7:409-416 [1996]). Oligosaccharides may also serve to target a given glycoprotein to certain molecules based upon specific recognition structures. For example, it has been reported that in agalactosylated IgG, the oligosaccharide moiety 'flips' out of the inter-CH2 space and terminal N-  
 25 acetylglucosamine residues become available to bind mannose binding protein (Malhotra *et al.*, *Nature Med.* 1:237-243 [1995]). Removal by glycopeptidase of the oligosaccharides from CAMPATH-1H (a recombinant humanized murine monoclonal IgG1 antibody which recognizes the CDw52 antigen of human lymphocytes) produced in Chinese Hamster Ovary (CHO) cells resulted in a complete reduction in complement mediated lysis (CMCL) (Boyd *et al.*, *Mol. Immunol.* 32:1311-1318 [1996]), while selective removal of sialic acid residues using neuraminidase resulted in no  
 30 loss of DMCL. Glycosylation of antibodies has also been reported to affect antibody-dependent cellular cytotoxicity (ADCC). In particular, CHO cells with tetracycline-regulated expression of  $\beta(1,4)$ -N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisecting GlcNAc, was reported to have improved ADCC activity (Umana *et al.*, *Mature Biotech.* 17:176-180 [1999]).

Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the  
 35 carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and

asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Glycosylation variants of antibodies are variants in which the glycosylation pattern of an antibody is altered. By altering is meant deleting one or more carbohydrate moieties found in the antibody, adding one or more carbohydrate moieties to the antibody, changing the composition of glycosylation (glycosylation pattern), the extent of glycosylation, etc.

Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites). Similarly, removal of glycosylation sites can be accomplished by amino acid alteration within the native glycosylation sites of the antibody.

The amino acid sequence is usually altered by altering the underlying nucleic acid sequence. Nucleic acid molecules encoding amino acid sequence variants of the anti-ErbB2 antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the anti-ErbB2 antibody.

The glycosylation (including glycosylation pattern) of antibodies may also be altered without altering the amino acid sequence or the underlying nucleotide sequence. Glycosylation largely depends on the host cell used to express the antibody. Since the cell type used for expression of recombinant glycoproteins, e.g. antibodies, as potential therapeutics is rarely the native cell, significant variations in the glycosylation pattern of the antibodies can be expected (see, e.g. Hse *et al.*, J. Biol. Chem. 272:9062-9070 [1997]). In addition to the choice of host cells, factors which affect glycosylation during recombinant production of antibodies include growth mode, media formulation, culture density, oxygenation, pH, purification schemes and the like. Various methods have been proposed to alter the glycosylation pattern achieved in a particular host organism including introducing or overexpressing certain enzymes involved in oligosaccharide production (U. S. Patent Nos. 5,047,335; 5,510,261 and 5,278,299). Glycosylation, or certain types of glycosylation, can be enzymatically removed from the glycoprotein, for example using endoglycosidase H (Endo H). In addition, the recombinant host cell can be genetically engineered, e.g. make defective in processing certain types of polysaccharides. These and similar techniques are well known in the art.

The glycosylation structure of antibodies can be readily analyzed by conventional techniques of carbohydrate analysis, including lectin chromatography, NMR, Mass spectrometry, HPLC, GPC, monosaccharide

compositional analysis, sequential enzymatic digestion, and HPAEC-PAD, which uses high pH anion exchange chromatography to separate oligosaccharides based on charge. Methods for releasing oligosaccharides for analytical purposes are also known, and include, without limitation, enzymatic treatment (commonly performed using peptide-N-glycosidase F/endo- $\beta$ -galactosidase), elimination using harsh alkaline environment to release mainly O-linked structures, and chemical methods using anhydrous hydrazine to release both N- and O-linked oligosaccharides.

(viii) *Screening for antibodies with the desired properties*

Techniques for generating antibodies have been described above. One may further select antibodies with certain biological characteristics, as desired.

For example, to identify growth inhibitory anti-ErbB2 antibodies, one may screen for antibodies which inhibit the growth of cancer cells which overexpress ErbB2. In one embodiment, the growth inhibitory antibody of choice is able to inhibit growth of SK-BR-3 cells in cell culture by about 20-100% and preferably by about 50-100% at an antibody concentration of about 0.5 to 30 g/ml. To identify such antibodies, the SK-BR-3 assay described in U.S. Patent No. 5,677,171 can be performed. According to this assay, SK-BR-3 cells are grown in a 1:1 mixture of F12 and DMEM medium supplemented with 10% fetal bovine serum, glutamine and penicillin streptomycin. The SK-BR-3 cells are plated at 20,000 cells in a 35mm cell culture dish (2mls/35mm dish). 0.5 to 30 g/ml of the anti-ErbB2 antibody is added per dish. After six days, the number of cells, compared to untreated cells are counted using an electronic COULTER cell counter. Those antibodies which inhibit growth of the SK-BR-3 cells by about 20-100% or about 50-100% may be selected as growth inhibitory antibodies.

To select for antibodies which induce cell death, loss of membrane integrity as indicated by, *e.g.*, PI, trypan blue or 7AAD uptake may be assessed relative to control. The preferred assay is the PI uptake assay using BT474 cells. According to this assay, BT474 cells (which can be obtained from the American Type Culture Collection (Rockville, MD)) are cultured in Dulbecco's Modified Eagle Medium (D-MEM):Ham's F-12 (50:50) supplemented with 10% heat-inactivated FBS (Hyclone) and 2 mM L-glutamine. (Thus, the assay is performed in the absence of complement and immune effector cells). The BT474 cells are seeded at a density of  $3 \times 10^6$  per dish in 100 x 20 mm dishes and allowed to attach overnight. The medium is then removed and replaced with fresh medium alone or medium containing 10 g/ml of the appropriate monoclonal antibody. The cells are incubated for a 3 day time period. Following each treatment, monolayers are washed with PBS and detached by trypsinization. Cells are then centrifuged at 1200rpm for 5 minutes at 4°C, the pellet resuspended in 3 ml ice cold  $\text{Ca}^{2+}$  binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM  $\text{CaCl}_2$ ) and aliquoted into 35 mm strainer-capped 12 x 75 tubes (1ml per tube, 3 tubes per treatment group) for removal of cell clumps. Tubes then receive PI (10 g/ml). Samples may be analyzed using a FACSCAN flow cytometer and FACSCONVERT CellQuest software (Becton Dickinson). Those antibodies which induce statistically significant levels of cell death as determined by PI uptake may be selected as cell death-inducing antibodies.

In order to select for antibodies which induce apoptosis, an annexin binding assay using BT474 cells is available. The BT474 cells are cultured and seeded in dishes as discussed in the preceding paragraph. The medium is

then removed and replaced with fresh medium alone or medium containing 10 g/ml of the monoclonal antibody. Following a three day incubation period, monolayers are washed with PBS and detached by trypsinization. Cells are then centrifuged, resuspended in  $\text{Ca}^{2+}$  binding buffer and aliquoted into tubes as discussed above for the cell death assay. Tubes then receive labeled annexin (*e.g.* annexin V-FTIC) (1 g/ml). Samples may be analyzed using a  
5 FACSCAN flow cytometer and FACSCONVERT CellQuest software (Becton Dickinson). Those antibodies which induce statistically significant levels of annexin binding relative to control are selected as apoptosis-inducing antibodies.

In addition to the annexin binding assay, a DNA staining assay using BT474 cells is available. In order to perform this assay, BT474 cells which have been treated with the antibody of interest as described in the preceding  
10 two paragraphs are incubated with 9 g/ml HOECHST 33342 for 2 hr at 37°C, then analyzed on an EPICS ELITE flow cytometer (Coulter Corporation) using MODFIT LT software (Verity Software House). Antibodies which induce a change in the percentage of apoptotic cells which is 2 fold or greater (and preferably 3 fold or greater) than untreated cells (up to 100% apoptotic cells) may be selected as pro-apoptotic antibodies using this assay.

To identify an antibody which blocks ligand activation of an ErbB receptor, the ability of the antibody to  
15 block ErbB ligand binding to cells expressing the ErbB receptor (*e.g.* in conjugation with another ErbB receptor with which the ErbB receptor of interest forms an ErbB hetero-oligomer) may be determined. For example, cells naturally expressing, or transfected to express, ErbB receptors of the ErbB hetero-oligomer may be incubated with the antibody and then exposed to labeled ErbB ligand. The ability of the anti-ErbB2 antibody to block ligand binding to the ErbB receptor in the ErbB hetero-oligomer may then be evaluated.

For example, inhibition of HRG binding to MCF7 breast tumor cell lines by anti-ErbB2 antibodies may be  
20 performed using monolayer MCF7 cultures on ice in a 24-well-plate format essentially as described in Example 1 below. Anti-ErbB2 monoclonal antibodies may be added to each well and incubated for 30 minutes.  $^{125}\text{I}$ -labeled rHRG 1<sub>177-224</sub> (25 pm) may then be added, and the incubation may be continued for 4 to 16 hours. Dose response curves may be prepared and an  $\text{IC}_{50}$  value may be calculated for the antibody of interest. In one embodiment, the  
25 antibody which blocks ligand activation of an ErbB receptor will have an  $\text{IC}_{50}$  for inhibiting HRG binding to MCF7 cells in this assay of about 50nM or less, more preferably 10nM or less. Where the antibody is an antibody fragment such as a Fab fragment, the  $\text{IC}_{50}$  for inhibiting HRG binding to MCF7 cells in this assay may, for example, be about 100nM or less, more preferably 50nM or less.

Alternatively, or additionally, the ability of the anti-ErbB2 antibody to block ErbB ligand-stimulated tyrosine  
30 phosphorylation of an ErbB receptor present in an ErbB hetero-oligomer may be assessed. For example, cells endogenously expressing the ErbB receptors or transfected to expressed them may be incubated with the antibody and then assayed for ErbB ligand-dependent tyrosine phosphorylation activity using an anti-phosphotyrosine monoclonal (which is optionally conjugated with a detectable label). The kinase receptor activation assay described in U.S. Patent No. 5,766,863 is also available for determining ErbB receptor activation and blocking of that activity by  
35 an antibody.

In one embodiment, one may screen for an antibody which inhibits HRG stimulation of p180 tyrosine phosphorylation in MCF7 cells. For example, the MCF7 cells may be plated in 24-well plates and monoclonal antibodies to ErbB2 may be added to each well and incubated for 30 minutes at room temperature; then rHRG 1<sub>177-244</sub> may be added to each well to a final concentration of 0.2 nM, and the incubation may be continued for 8 minutes. Media may be aspirated from each well, and reactions may be stopped by the addition of 100  $\mu$ l of SDS sample buffer (5% SDS, 25 mM DTT, and 25 mM Tris-HCl, pH 6.8). Each sample (25  $\mu$ l) may be electrophoresed on a 4-12% gradient gel (Novex) and then electrophoretically transferred to polyvinylidene difluoride membrane. Antiphosphotyrosine (at 1  $\mu$ g/ml) immunoblots may be developed, and the intensity of the predominant reactive band at  $M_r$  ~180,000 may be quantified by reflectance densitometry. The antibody selected will preferably significantly inhibit HRG stimulation of p180 tyrosine phosphorylation to about 0-35% of control in this assay. A dose-response curve for inhibition of HRG stimulation of p180 tyrosine phosphorylation as determined by reflectance densitometry may be prepared and an  $IC_{50}$  for the antibody of interest may be calculated. In one embodiment, the antibody which blocks ligand activation of an ErbB receptor will have an  $IC_{50}$  for inhibiting HRG stimulation of p180 tyrosine phosphorylation in this assay of about 50nM or less, more preferably 10nM or less. Where the antibody is an antibody fragment such as a Fab fragment, the  $IC_{50}$  for inhibiting HRG stimulation of p180 tyrosine phosphorylation in this assay may, for example, be about 100nM or less, more preferably 50nM or less.

One may also assess the growth inhibitory effects of the antibody on MDA-MB-175 cells, *e.g.* essentially as described in Schaefer *et al. Oncogene* 15:1385-1394 (1997). According to this assay, MDA-MB-175 cells may be treated with an anti-ErbB2 monoclonal antibody (10  $\mu$ g/ml) for 4 days and stained with crystal violet. Incubation with an anti-ErbB2 antibody may show a growth inhibitory effect on this cell line similar to that displayed by monoclonal antibody 2C4. In a further embodiment, exogenous HRG will not significantly reverse this inhibition. Preferably, the antibody will be able to inhibit cell proliferation of MDA-MB-175 cells to a greater extent than monoclonal antibody 4D5 (and optionally to a greater extent than monoclonal antibody 7F3), both in the presence and absence of exogenous HRG.

In one embodiment, the anti-ErbB2 antibody of interest may block heregulin dependent association of ErbB2 with ErbB3 in both MCF7 and SK-BR-3 cells as determined in a co-immunoprecipitation experiment substantially more effectively than monoclonal antibody 4D5, and preferably substantially more effectively than monoclonal antibody 7F3.

To screen for antibodies which bind to an epitope on ErbB2 bound by an antibody of interest, a routine cross-blocking assay such as that described in *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, or additionally, epitope mapping can be performed by methods known in the art (see, *e.g.* Figs. 1A and 1B herein).

The results obtained in the cell-based assays described above can then be followed by testing in animal, *e.g.* murine, models, and human clinical trials. In particular, the inability or limited ability of an antibody to treat ErbB2

overexpressing tumors can be demonstrated in the transgenic mouse model disclosed in the present application as described in the Examples below.

C. Anti-ErbB antibody-maytansinoid conjugates (immunoconjugates)

5 Anti-ErbB antibody-maytansinoid conjugates are prepared by chemically linking an anti-ErbB antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. Maytansinoids are well known in the art and can be synthesized by known techniques or isolated from natural sources. Suitable maytansinoids are disclosed, for example, in U.S. Patent No. 5,208,020 and in the other patents and nonpatent publications referred to hereinabove. Preferred maytansinoids are maytansinol and  
10 maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters.

There are many linking groups known in the art for making antibody-maytansinoid conjugates, including, for example, those disclosed in U.S. Patent No. 5,208,020 or EP Patent 0 425 235 B1, and Chari *et al. Cancer Research* 52: 127-131 (1992). The linking groups include disulfide groups, thioether groups, acid labile groups, photolabile  
15 groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred.

Conjugates of the antibody and maytansinoid may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active  
20 esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Carlsson *et al., Biochem. J.* 173:723-737 [1978]) and N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP) to provide for  
25 a disulfide linkage.

The linker may be attached to the maytansinoid molecule at various positions, depending on the type of the link. For example, an ester linkage may be formed at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group using conventional coupling techniques. In a preferred embodiment, the linkage is formed at the C-3  
30 position of maytansinol or a maytansinol analogue.

D. Pharmaceutical formulations

Therapeutic formulations of the antibody-maytansinoid conjugates used in accordance with the present invention are prepared for storage by mixing an antibody having the desired degree of purity with optional  
35 pharmaceutically acceptable carriers, excipients or stabilizers (*Remington's Pharmaceutical Sciences* 16th edition,

Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (*e.g.* Zn-protein complexes); and/or non-ionic surfactants such as TWEEN, PLURONICS or polyethylene glycol (PEG). Preferred lyophilized anti-ErbB2 antibody formulations are described in WO 97/04801, expressly incorporated herein by reference.

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide antibodies or antibody-maytansinoid conjugates which bind to EGFR, ErbB2 (*e.g.* an antibody which binds a different epitope on ErbB2), ErbB3, ErbB4, or vascular endothelial factor (VEGF) in the one formulation. Alternatively, or additionally, the composition may further comprise a chemotherapeutic agent, cytotoxic agent, cytokine, growth inhibitory agent, anti-hormonal agent, and/or cardioprotectant. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.* films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

E. Treatment with the anti-ErbB2 antibody-maytansinoid conjugates

It is contemplated that, according to the present invention, the anti-ErbB2 antibody-maytansinoid conjugates may be used to treat various diseases or disorders. Exemplary conditions or disorders include benign or malignant tumors; leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic disorders.

5 Generally, the disease or disorder to be treated is cancer. Examples of cancer to be treated herein include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (*e.g.* epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, 10 pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.

The cancer will comprise ErbB-expressing cells, such that an anti-ErbB antibody herein is able to bind to the 15 cancer, and will be typically characterized by overexpression of the ErbB receptor. In a preferred embodiment, the cancer comprises ErbB2-expressing cells, even more preferably, cells which are characterized by overexpression of the ErbB2 receptor. To determine ErbB, *e.g.* ErbB2 expression in the cancer, various diagnostic/prognostic assays are available. In one embodiment, ErbB2 overexpression may be analyzed by IHC, *e.g.* using the HERCEPTEST® (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a ErbB2 20 protein staining intensity criteria as follows:

Score 0

no staining is observed or membrane staining is observed in less than 10% of tumor cells.

Score 1+

a faint/barely perceptible membrane staining is detected in more than 10% of the tumor cells. The cells are only 25 stained in part of their membrane.

Score 2+

a weak to moderate complete membrane staining is observed in more than 10% of the tumor cells.

Score 3+

a moderate to strong complete membrane staining is observed in more than 10% of the tumor cells.

30 Those tumors with 0 or 1+ scores for ErbB2 overexpression assessment may be characterized as not overexpressing ErbB2, whereas those tumors with 2+ or 3+ scores may be characterized as overexpressing ErbB2.

Alternatively, or additionally, FISH assays such as the INFORM (sold by Ventana, Arizona) or PATHVISION (Vysis, Illinois) may be carried out on formalin-fixed, paraffin-embedded tumor tissue to determine the extent (if any) of ErbB2 overexpression in the tumor.



In one embodiment, the cancer will be one which expresses (and may overexpress) EGFR. Examples of cancers which may express/overexpress EGFR include squamous cell cancer (*e.g.* epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including  
5 gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.

Preferably, the immunoconjugates of the present invention and/or ErbB, *e.g.* ErbB2 or EGFR protein to which  
10 they are bound are internalized by the cell, resulting in increased therapeutic efficacy of the immunoconjugate in killing the cancer cell to which they bind. In a preferred embodiment, the cytotoxic agent (maytansinoid) targets or interferes with nucleic acid in the cancer cell.

The treatment of the present invention targets ErbB overexpressing tumors that do not respond, or respond poorly, to treatment with an unconjugated anti-ErbB antibody. Such patients might have received prior treatment with  
15 an anti-ErbB antibody not conjugated to a maytansinoid moiety, where the prior treatment either did not result in significant improvement, or resulted in transient response. Prior treatment of any particular patient with an unconjugated anti-ErbB antibody is, however, not a prerequisite of identifying patients who are candidates for treatment in accordance with the present invention. An ordinary skilled physician can readily identify patients who  
20 are expected to benefit from treatment with the immunoconjugates of the present invention based on publicly available clinical data his or her own experience. Treatment of mammals, and in particular human patients, with or without prior treatment with an (unconjugated) anti-ErbB antibody is specifically within the scope of the present invention.

The anti-ErbB antibody-maytansinoid conjugates are administered to a mammal, preferably to a human patient in accord with known methods, such as intravenous administration, *e.g.*, as a bolus or by continuous infusion  
25 over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous or subcutaneous administration of the antibody is preferred.

Other therapeutic regimens may be combined with the administration of the anti-ErbB antibody-maytansinoid conjugates. The combined administration includes coadministration, using separate formulations or a single  
30 pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities.

In one preferred embodiment, the patient is treated with two or more different anti-ErbB antibodies, at least one of which is in the form of a maytansinoid conjugate. For example, the patient may be treated with a first anti-ErbB2 antibody-maytansinoid conjugate in which the antibody is growth inhibitory (*e.g.* HERCEPTIN®), and a second anti-ErbB2 antibody or antibody-immunoconjugate, *e.g.* an antibody-maytansinoid conjugate which blocks ligand  
35 activation of an ErbB receptor (*e.g.* 2C4 or a humanized and/or affinity matured variant thereof) or induces apoptosis

of an ErbB2-overexpressing cell (*e.g.* 7C2, 7F3 or humanized variants thereof). In another embodiment, the treatment involves the administration of antibodies that specifically bind two or more different ErbB receptors, such as, for example, ErbB2 and EGFR receptors, where at least one of the anti-ErbB antibodies is administered as a maytansinoid conjugate. Preferably such combined therapy results in a synergistic therapeutic effect.

5           It may also be desirable to combine administration of the anti-ErbB antibody-maytansinoid conjugates, with administration of an antibody directed against another tumor-associated antigen, which is not member of the ErbB family of receptors. The other antibody in this case may, for example, bind to vascular endothelial growth factor (VEGF), and may be in the form of a maytansinoid conjugate, or another immunoconjugate.

10           In one embodiment, the treatment of the present invention involves the combined administration of an anti-ErbB2 antibody-maytansinoid conjugate (or conjugates) and one or more chemotherapeutic agents or growth inhibitory agents, including coadministration of cocktails of different chemotherapeutic agents. Preferred chemotherapeutic agents include taxanes (such as paclitaxel and doxorubicin) and/or anthracycline antibiotics. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in  
15           Chemotherapy Service Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992).

          The antibody-maytansinoid conjugates may be combined with an anti-hormonal compound; *e.g.*, an anti-estrogen compound such as tamoxifen; an anti-progesterone such as onapristone (see, EP 616 812); or an anti-androgen such as flutamide, in dosages known for such molecules. Where the cancer to be treated is hormone independent cancer, the patient may previously have been subjected to anti-hormonal therapy and, after the cancer  
20           becomes hormone independent, the anti-ErbB2 antibody (and optionally other agents as described herein) may be administered to the patient.

          Sometimes, it may be beneficial to also coadminister a cardioprotectant (to prevent or reduce myocardial dysfunction associated with the therapy) or one or more cytokines to the patient. In addition to the above therapeutic regimes, the patient may be subjected to surgical removal of cancer cells and/or radiation therapy.

25           Suitable dosages for any of the above coadministered agents are those presently used and may be lowered due to the combined action (synergy) of the agent and anti-ErbB2 antibody.

          For the prevention or treatment of disease, the appropriate dosage of antibody-maytansinoid conjugates will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and  
30           response to the antibody, and the discretion of the attending physician. The antibody-maytansinoid conjugate is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 g/kg to 15 mg/kg (*e.g.* 0.1-20mg/kg) of antibody-maytansinoid conjugate is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 g/kg to 100 mg/kg or more, depending on the  
35           factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the

treatment is sustained until a desired suppression of disease symptoms occurs. A preferred dosing regimen comprises administering an initial loading dose of about 4 mg/kg, followed by a weekly maintenance dose of about 2 mg/kg of the anti-ErbB2 antibody-maytansinoid conjugate. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

5

#### F. Articles of Manufacture

In another embodiment of the invention, an article of manufacture containing materials useful for the treatment of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an anti-ErbB2 antibody-maytansinoid conjugate. The label or package insert indicates that the composition is used for treating the condition of choice, such as cancer. In one embodiment, the label or package insert indicates that the composition comprising the antibody which binds ErbB2 can be used to treat cancer which expresses an ErbB receptor selected from the group consisting of epidermal growth factor receptor (EGFR), ErbB2, ErbB3 and ErbB4, preferably EGFR. In addition, the label or package insert may indicate that the patient to be treated is one having cancer characterized by excessive activation of an ErbB receptor selected from EGFR, ErbB2, ErbB3 or ErbB4. For example, the cancer may be one which overexpresses one of these receptors and/or which overexpresses an ErbB ligand (such as TGF- $\beta$ ). The label or package insert may also indicate that the composition can be used to treat cancer, wherein the cancer is not characterized by overexpression of the ErbB2 receptor. For example, whereas the present package insert for HERCEPTIN<sup>®</sup> indicates that the antibody is used to treat patients with metastatic breast cancer whose tumors overexpress the ErbB2 protein, the package insert herein may indicate that the antibody or composition is used to treat cancer that does not respond, or respond poorly, to treatment with HERCEPTIN<sup>®</sup>. In other embodiments, the package insert may indicate that the antibody-maytansinoid conjugate or composition can be used also to treat hormone independent cancer, prostate cancer, colon cancer or colorectal cancer. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises a maytansinoid conjugate of a first antibody which binds ErbB2 and inhibits growth of cancer cells which overexpress ErbB2; and (b) a second container with a composition contained therein, wherein the composition comprises a second antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor, or a conjugate of this second antibody with a maytansinoid. The article of manufacture in this embodiment of the invention may further comprises a package insert indicating that the first and second compositions can be used to treat cancer. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI),

phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Further details of the invention are illustrated in the following non-limiting examples.

5

### Example 1

#### Production, Characterization and Humanization of Anti-ErbB2 Monoclonal Antibody 4D5

The murine monoclonal antibody 4D5 which specifically binds the extracellular domain of ErbB2 was produced as described in Fendly *et al.*, *Cancer Research* 50:1550-1558 (1990). Briefly, NIH 3T3/HER2-3<sub>400</sub> cells (expressing approximately  $1 \times 10^5$  ErbB2 molecules/cell) produced as described in Hudziak *et al Proc. Natl. Acad. Sci. (USA)* 84:7158-7163 (1987) were harvested with phosphate buffered saline (PBS) containing 25mM EDTA and used to immunize BALB/c mice. The mice were given injections i.p. of  $10^7$  cells in 0.5ml PBS on weeks 0, 2, 5 and 7. The mice with antisera that immunoprecipitated <sup>32</sup>P-labeled ErbB2 were given i.p. injections of a wheat germ agglutinin-Sephrose (WGA) purified ErbB2 membrane extract on weeks 9 and 13. This was followed by an i.v. injection of 0.1 ml of the ErbB2 preparation and the splenocytes were fused with mouse myeloma line X63-Ag8.653. Hybridoma supernatants were screened for ErbB2-binding by ELISA and radioimmunoprecipitation.

15

#### Epitope mapping and characterization

The ErbB2 epitope bound by monoclonal antibody 4D5 was determined by competitive binding analysis (Fendly *et al. Cancer Research* 50:1550 -1558 (1990)). Cross-blocking studies were done by direct fluorescence on intact cells using the PANDEX™ Screen Machine to quantitate fluorescence. The monoclonal antibody was conjugated with fluorescein isothiocyanate (FITC), using established procedures (Wofsy *et al. Selected Methods in Cellular Immunology*, p. 287, Mishel and Schiigi (eds.) San Francisco: W.J. Freeman Co. (1980)). Confluent monolayers of NIH 3T3/HER2-3<sub>400</sub> cells were trypsinized, washed once, and resuspended at  $1.75 \times 10^6$  cell/ml in cold PBS containing 0.5% bovine serum albumin (BSA) and 0.1% NaN<sub>3</sub>. A final concentration of 1% latex particles (IDC, Portland, OR) was added to reduce clogging of the PANDEX™ plate membranes. Cells in suspension, 20  $\mu$ l, and 20  $\mu$ l of purified monoclonal antibodies (100  $\mu$ g/ml to 0.1  $\mu$ g/ml) were added to the PANDEX™ plate wells and incubated on ice for 30 minutes. A predetermined dilution of the FITC-labeled monoclonal antibody in 20  $\mu$ l was added to each well, incubated for 30 minutes, washed, and the fluorescence was quantitated by the PANDEX™. Monoclonal antibodies were considered to share an epitope if each blocked binding of the other by 50% or greater in comparison to an irrelevant monoclonal antibody control. In this experiment, monoclonal antibody 4D5 was assigned epitope I (amino acid residues from about 529 to about 625, inclusive within the ErbB2 extracellular domain (see SEQ ID NO: 3)).

20

25

30

35

The growth inhibitory characteristics of monoclonal antibody 4D5 were evaluated using the breast tumor cell line, SK-BR-3 (see Hudziak *et al. Molec. Cell. Biol.* 9(3):1165-1172 (1989)). Briefly, SK-BR-3 cells were detached by using 0.25% (vol/vol) trypsin and suspended in complete medium at a density of  $4 \times 10^5$  cells per ml. Aliquots of 100  $\mu$ l ( $4 \times 10^4$  cells) were plated into 96-well microdilution plates, the cells were allowed to adhere, and 100  $\mu$ l of media alone or media containing monoclonal antibody (final concentration 5  $\mu$ g/ml) was then added. After 72 hours,

plates were washed twice with PBS (pH 7.5), stained with crystal violet (0.5% in methanol), and analyzed for relative cell proliferation as described in Sugarman *et al. Science* 230:943-945 (1985). Monoclonal antibody 4D5 inhibited SK-BR-3 relative cell proliferation by about 56%.

Monoclonal antibody 4D5 was also evaluated for its ability to inhibit HRG-stimulated tyrosine phosphorylation of proteins in the  $M_r$  180,000 range from whole-cell lysates of MCF7 cells (Lewis *et al. Cancer Research* 56:1457-1465 (1996)). MCF7 cells are reported to express all known ErbB receptors, but at relatively low levels. Since ErbB2, ErbB3, and ErbB4 have nearly identical molecular sizes, it is not possible to discern which protein is becoming tyrosine phosphorylated when whole-cell lysates are evaluated by Western blot analysis. However, these cells are ideal for HRG tyrosine phosphorylation assays because under the assay conditions used, in the absence of exogenously added HRG, they exhibit low to undetectable levels of tyrosine phosphorylation proteins in the  $M_r$  180,000 range.

MCF7 cells were plated in 24-well plates and monoclonal antibodies to ErbB2 were added to each well and incubated for 30 minutes at room temperature; then rHRG 1<sub>177-244</sub> was added to each well to a final concentration of 0.2 nM, and the incubation was continued for 8 minutes. Media was carefully aspirated from each well, and reactions were stopped by the addition of 100  $\mu$ l of SDS sample buffer (5% SDS, 25 mM DTT, and 25 mM Tris-HCl, pH 6.8). Each sample (25  $\mu$ l) was electrophoresed on a 4-12% gradient gel (Novex) and then electrophoretically transferred to polyvinylidene difluoride membrane. Antiphosphotyrosine (4G10, from UBI, used at 1  $\mu$ g/ml) immunoblots were developed, and the intensity of the predominant reactive band at  $M_r$  180,000 was quantified by reflectance densitometry, as described previously (Holmes *et al. Science* 256:1205-1210 (1992); Sliwkowski *et al. J. Biol. Chem.* 269:14661-14665 (1994)).

Monoclonal antibody 4D5 significantly inhibited the generation of a HRG-induced tyrosine phosphorylation signal at  $M_r$  180,000. In the absence of HRG, but was unable to stimulate tyrosine phosphorylation of proteins in the  $M_r$  180,000 range. Also, this antibody does not cross-react with EGFR (Fendly *et al. Cancer Research* 50:1550-1558 (1990)), ErbB3, or ErbB4. Monoclonal antibody 4D5 was able to block HRG stimulation of tyrosine phosphorylation by 50%.

The growth inhibitory effect of monoclonal antibody 4D5 on MDA-MB-175 and SK-BR-3 cells in the presence or absence of exogenous rHRG 1 was assessed (Schaefer *et al. Oncogene* 15:1385-1394 (1997)). ErbB2 levels in MDA-MB-175 cells are 4-6 times higher than the level found in normal breast epithelial cells and the ErbB2-ErbB4 receptor is constitutively tyrosine phosphorylated in MDA-MB-175 cells. Monoclonal antibody 4D5 was able to inhibit cell proliferation of MDA-MB-175 cells, both in the presence and absence of exogenous HRG. Inhibition of cell proliferation by 4D5 is dependent on the ErbB2 expression level (Lewis *et al. Cancer Immunol. Immunother.* 37:255-263 (1993)). A maximum inhibition of 66% in SK-BR-3 cells could be detected. However this effect could be overcome by exogenous HRG.

#### Humanization

The murine monoclonal antibody 4D5 was humanized, using a novel "gene conversion mutagenesis" strategy, as described in U.S. Patent No. 5,821,337, the entire disclosure of which is hereby expressly incorporated by reference. The humanized monoclonal antibody 4D5 used in the following experiments is designated huMAb4D5-8. This antibody is of IgG1 isotype.

5

## Example 2

### HERCEPTIN<sup>®</sup>-DM1 conjugates

#### 1. Purification of HERCEPTIN<sup>®</sup>

HERCEPTIN<sup>®</sup> (huMAb4D5-8, rhuMAb HER2, U.S. Patent No. 5,821,337) (1 vial containing 440 mg antibody) was dissolved in 50 mL MES buffer (25 mM MES, 50 mM NaCl, pH 5.6). The sample was loaded on a cation exchange column (Sephacrose S, 15 cm x 1.7 cm) that had been equilibrated in the same buffer. The column was then washed with the same buffer (5 column volumes). HERCEPTIN<sup>®</sup> was eluted by raising the NaCl concentration of the buffer to 200 mM. Fractions containing the antibody were pooled, diluted to 10 mg/mL, and dialyzed into a buffer containing 50 mM potassium phosphate, 50 mM NaCl, 2 mM EDTA, pH 6.5.

15

#### 2. Modification of HERCEPTIN<sup>®</sup> with SPP

The purified HERCEPTIN<sup>®</sup> antibody was modified with N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP) to introduce dithiopyridyl groups. The antibody (376.0 mg, 8 mg/mL) in 44.7 mL of 50 mM potassium phosphate buffer (pH 6.5) containing NaCl (50 mM) and EDTA (1 mM) was treated with SPP (5.3 molar equivalents in 2.3 mL ethanol). After incubation for 90 minutes under argon at ambient temperature, the reaction mixture was gel filtered through a Sephadex G25 column equilibrated with 35 mM sodium citrate, 154 mM NaCl, 2 mM EDTA. Antibody containing fractions were pooled and assayed. The degree of modification of the antibody was determined as described above. Recovery of the modified antibody (HERCEPTIN<sup>®</sup>-SPP-Py) was 337 mg (89.7%) with 4.5 releasable 2-thiopyridine groups linked per antibody.

20

#### 3. Conjugation of HERCEPTIN<sup>®</sup>-SPP-Py with DM1

The modified antibody (337.0 mg, 9.5  $\mu$ mol of releasable 2-thiopyridine groups) was diluted with the above 35 mM sodium citrate buffer, pH 6.5, to a final concentration of 2.5 mg/mL. DM1 (the structure of which is shown in Figure 1) (1.7 equivalents, 16.1  $\mu$ mol) in 3.0 mM dimethylacetamide (DMA, 3% v/v in the final reaction mixture) was then added to the antibody solution. The reaction proceeded at ambient temperature under argon for 20 hours. The structure of HERCEPTIN<sup>®</sup>-DM1 conjugates is illustrated in Figure 2.

25

30

The reaction was loaded on a Sephacryl S300 gel filtration column (5.0 cm x 90.0 cm, 1.77 L) equilibrated with 35 mM sodium citrate, 154 mM NaCl, pH 6.5. The flow rate was 5.0 mL/min and 65 fractions (20.0 mL each) were collected. A major peak centered around fraction No. 47 (Figure 3). The major peak comprises monomeric HERCEPTIN<sup>®</sup>-DM1. Fractions 44-51 were pooled and assayed. The number of DM1 drug molecules linked per

antibody molecule was determined by measuring the absorbance at 252 nm and 280 nm, and found to be 3.7 drug molecules per antibody molecule.

### Example 3

#### Transgenic Animals

5 In order to improve the clinical activity of HERCEPTIN®, a transgenic HER2 mouse model was developed in which novel HER2-directed therapies could be tested preclinically. Tumors arise readily in transgenic mice that express a mutationally activated form of *neu*, the rat homolog of HER2, but the HER2 that is overexpressed in breast cancers is not mutated and tumor formation is much less robust in transgenic mice that overexpress nonmutated HER2  
10 (Webster *et al.*, *Semin. Cancer Biol.* 5: 69-76 [1994]). To improve tumor formation with nonmutated HER2, a strategy was used to further enhance overexpression of nonmutated HER2 in a transgenic mouse.

Any promoter that promotes expression of HER2 in epithelial cells in the mouse mammary gland can be used in the disclosed constructs. Many of the milk protein genes are transcribed by promoter/enhancer elements that are specifically active in mammary glands. Milk protein genes include those genes encoding caseins ( $\alpha$ -S<sub>1</sub> and  $\beta$ ),  $\beta$ -  
15 lactoglobulin,  $\alpha$ -lactalbumin, and whey acidic protein. The ovine  $\beta$ -lactoglobulin promoter is well characterized and widely used in the art (Whitelaw *et al.*, *Biochem J.* 286: 31-39, [1992]). However, similar fragments of promoter DNA from other species are also suitable. A preferred promoter is the promoter derived from the Long Terminal Repeat (LTR) of the Mouse Mammary Tumor Virus (MMTV). A HER2 transgene construct of the present invention was generated using the MMTV LTR promoter.

20 To improve tumor formation with nonmutated HER2, we have made transgenic mice using a HER2 cDNA plasmid in which an upstream ATG was deleted in order to prevent initiation of translation at such upstream ATG codons, which would otherwise reduce the frequency of translation initiation from the downstream authentic initiation codon of HER2 (for example, see Child *et al.*, *J. Biol. Chem.* 274: 24335-24341 [1999]). Additionally, a chimeric intron was added to the 5' end, which should also enhance the level of expression as reported earlier (Neuberger and  
25 Williams, *Nucleic Acids Res.* 16: 6713 [1988]; Buchman and Berg, *Mol. Cell. Biol.* 8: 4395 [1988]; Brinster *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 836 [1988]). The chimeric intron was derived from a Promega vector, pCI-neo mammalian expression vector (bp 890-1022). The cDNA 3'-end is flanked by human growth hormone exons 4 and 5, and polyadenylation sequences. Moreover, FVB mice were used because this strain is more susceptible to tumor development. The promoter from MMTV-LTR was used to ensure tissue-specific HER2 expression in the mammary  
30 gland. Animals were fed the AIN 76A diet in order to increase susceptibility to tumor formation (Rao *et al.*, *Breast Cancer Res. and Treatment* 45: 149-158 [1997]). The nucleotides sequence of this transgene plasmid construct (SEQ ID NO: 1) is shown in Figure 4.

Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Taconic (Germantown, N.Y.). Many strains are suitable, but FVB female mice are preferred because of their higher  
35 susceptibility to tumor formation. FVB males were used for mating and vasectomized CD.1 studs were used to

stimulate pseudopregnancy. Vasectomized mice can be obtained from any commercial supplier. Founders were bred with either FVB mice or with 129/BL6 x FVB p53 heterozygous mice. The mice with heterozygosity at p53 allele were used to potentially increase tumor formation. However, this has proven unnecessary. Therefore, some F1 tumors are of mixed strain. Founder tumors are FVB only. Six founders were obtained with some developing tumors without having litters.

#### Example 4

##### HER2 transgenic mouse as a tumor model to evaluate HER2-directed therapies

Mammary gland biopsies of one founder transgenic mouse made as described in Example 3, showed 3+ expression of HER2, as determined by immunohistochemical staining, at about 2 months of age. The amount of HER2 extracellular domain (ECD) shed into serum was measured and found to be about 1.2 ng/ml (Huang et al., *supra*). This mouse subsequently developed a mammary tumor at 5 months of age, after bearing 4 litters. The tumor was surgically resected under aseptic conditions and minced into small pieces, 2 mm<sup>3</sup>, which were then transplanted into the mammary fat pad of wild-type FVB female mice. Tumors developed in 22 of 31 recipient mice, with a latency of 5 weeks. With subsequent passage, tumors developed with shorter latency and grew more rapidly, and tumor incidence increased to >95% of recipients. HER2 expression, as determined by immunohistochemical staining, was 3+ but heterogeneous in the primary tumor, but became uniformly 3+ after the first passage.

Treatment of tumor-bearing mice with HERCEPTIN<sup>®</sup> or 4D5, the murine antibody from which humanized HERCEPTIN<sup>®</sup> was derived, had only a modest effect on the growth of the transplanted tumors (Figure 5). HER2 expression was 3+ in tumors that grew during HERCEPTIN<sup>®</sup> or 4D5 therapy, indicating that there was no selection of HER2-negative tumors. Moreover, cy3-HERCEPTIN<sup>®</sup> was detected decorating tumor cells after injection into tumor-bearing mice, indicating that the lack of efficacy was not due to failure of the antibody to access the tumor.

Based on the persistent expression of HER2 and the failure of this tumor model to respond to HERCEPTIN<sup>®</sup>, a novel approach was tested, using HERCEPTIN<sup>®</sup> conjugated to maytansinoid DM1 as described in Example 3. Figure 5 shows that the HERCEPTIN<sup>®</sup>-DM1 conjugate has dramatic anti-tumor activity in this model. RITUXAN<sup>®</sup>, an unrelated anti-CD20 monoclonal antibody, was used as a negative control for these studies. There was little response to HERCEPTIN<sup>®</sup> compared to the control antibody, RITUXAN<sup>®</sup>, but there was striking anti-tumor activity of the maytansinoid conjugate of HERCEPTIN<sup>®</sup>. As shown in Figure 5, all of the mice treated with HERCEPTIN<sup>®</sup>-maytansinoid showed striking shrinkage of their tumors, though none of the tumors disappeared. After approximately 4 weeks, tumors began to regrow. Five animals were sacrificed at this time. Their tumors were found to express HER2 at 3+ levels. Thus, there was no selection for HER2-negative tumors. Based on this observation, the remaining 3 mice were treated with HERCEPTIN<sup>®</sup>-maytansinoid for 5 consecutive days. The tumors again regressed in response to the treatment.



All references cited through the specification, and the references cited therein, are hereby expressly incorporated by reference.

Deposit of Biological Material

5           The following hybridoma cell lines have been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, USA (ATCC):

	<b>Antibody Designation</b>	<b>ATCC No.</b>	<b>Deposit Date</b>
	7C2	ATCC HB-12215	October 17, 1996
	7F3	ATCC HB-12216	October 17, 1996
10	4D5	ATCC CRL 10463	May 24, 1990
	2C4	ATCC HB-12697	April 8, 1999

          This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty).  
15       This assures maintenance of viable cultures for 30 years from the date of the deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents  
20       and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.12 with particular reference to 886 OG 638).

          In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of  
25       such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)

          The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent  
30       laws.

          The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiments are intended to illustrate only certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that  
35       the written description herein contained is inadequate to enable the practice of any aspect of the invention, including

the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that they represent. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

- 5           It is understood that the application of the teachings of the present invention to a specific problem or situation will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and representative processes for their isolation, use, and manufacture appear below, but should not be construed to limit the invention.

What is claimed is:

1. A method for the treatment of a tumor in a mammal, wherein the tumor is characterized by the overexpression of an ErbB receptor and does not respond, or responds poorly, to treatment with an anti-ErbB antibody, comprising administering to the mammal a therapeutically effective amount of a conjugate of the anti-ErbB antibody  
5 with a maytansinoid.
2. The method of claim 1 wherein the mammal is human.
3. The method of claim 2 wherein the ErbB receptor is selected from the group consisting of ErbB1  
10 (EGFR), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4).
4. The method of claim 3 wherein the anti-ErbB antibody is a growth inhibitory antibody.
5. The method of claim 3 wherein the anti-ErbB antibody induces cell death.  
15
6. The method of claim 3 wherein the anti-ErbB antibody induces apoptosis.
7. The method of claim 3 wherein the antibody is an anti-ErbB2 antibody.
8. The method of claim 7 wherein the tumor is cancer.  
20
9. The method of claim 8 wherein the cancer is selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate and bladder cancer.
10. The method of claim 9 wherein the cancer is breast cancer.  
25
11. The method of claim 10 wherein the breast cancer overexpresses ErbB2 at a 2+ level or more.
12. The method of claim 11 wherein the breast cancer overexpresses ErbB2 at a 3+ level.  
30
13. The method of claim 12 wherein the antibody has a biological characteristic of a 4D5 monoclonal antibody.
14. The method of claim 13 wherein the antibody binds essentially the same epitope as a 4D5  
35 monoclonal antibody.

15. The method of claim 13 wherein the antibody is the monoclonal antibody 4D5 (ATCC CRL 10463).

16. The method of claim 13 wherein the antibody is humanized.

5

17. The method of claim 16 wherein the antibody is selected from the group consisting of humanized antibodies huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN®).

10

18. The method of claim 17 wherein the antibody is humanized antibody huMAb4D5-8 (HERCEPTIN®).

19. The method of claim 3 wherein the antibody is an antibody fragment.

20. The method of claim 19 wherein the antibody fragment is a Fab fragment.

15

21. The method of claim 3 wherein the maytansinoid is maytansine.

22. The method of claim 3 wherein the maytansinoid is maytansinol.

20

23. The method of claim 3 wherein the maytansinoid is a maytansinol ester.

24. The method of claim 23 wherein the maytansinoid is a C-3 ester of maytansinol.

25. The method of claim 24 wherein the maytansinoid is DM1 shown in Figure 1.

25

26. The method of claim 3 wherein the antibody and maytansinoid are conjugated by a bispecific chemical linker.

30

27. The method of claim 26 wherein said chemical linker is N-succinimidyl-4-(2-pyridylthio)propanoate (SPDP) or N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP).

28. The method of claim 3 wherein the antibody and maytansinoid are conjugated by a linking group selected from the group consisting of a disulfide, thioether, acid labile, photolabile, peptidase labile, and esterase labile group.

35

29. The method of claim 28 wherein the linking group is a disulfide or a thioether group.
30. The method of claim 29 wherein the linking group is a disulfide group.
- 5 31. The method of claim 3 wherein the conjugate comprises 1 to about 10 maytansinoid molecules per antibody molecule.
32. The method of claim 31 wherein the conjugate comprises from about 3 to about 5 maytansinoid molecules per antibody molecule.
- 10 33. The method of claim 7 further comprising the administration of a second antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor.
34. The method of claim 33 wherein the second antibody comprises monoclonal antibody 2C4 or  
15 humanized 2C4.
35. The method of claim 33 wherein said second antibody is conjugated with a cytotoxic agent.
36. The method of claim 35 wherein the cytotoxic agent is a maytansinoid.
- 20 37. An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an anti-ErbB antibody-maytansinoid conjugate, and further comprising a package insert or label indicating that the composition can be used to treat cancer characterized by the overexpression of an ErbB receptor.
- 25 38. The article of manufacture of claim 37 wherein said package insert or label indicates that the composition can be used to treat cancer characterized by the overexpression of an ErbB2 receptor.
39. The article of manufacture of claim 38 wherein the cancer is breast cancer.
- 30 40. The article of manufacture of claim 38 wherein the cancer is characterized by the overexpression of an ErbB2 receptor at a 2+ level or above.
41. The article of manufacture of claim 40 wherein the cancer is characterized by the overexpression of an ErbB2 receptor at a 3+ level.
- 35




FIGURE 1

FIG. 1

FIGURE 2




FIG 2






FIGURE 2

```

          rmaI          maeI          rmaI
          sau3AI      sau3AI      maeI
          mboI/ndeII  mboI/ndeII
          dpnII      nheI      nlaIII  tseI
          dpnII      cac8I      tseI    fnu4HI/bsoFI
          pvuI/bspCI  mseI      nlaIII  tseI    nspHI  bbvI
          mcrI      bsiHKA1  tspS09I  fnuDII/mvNI  cac8I  scfI
          bsiEI      bmyI      aseI/asnI/vsPI  bstUI  bfaI  aluI  nspI  pstI
          taqI      apaLI/snoI  rcaI      bsh1236I  fnu4HI/bsoFI  cac8I
          aluI  dpnI  alw44I/snoI  bspHI  nruI  aluI  bbvI  cac8I  bsgI
          1  AAGCTCGATC  GGTGCACATT  AATTTCATGAT  CGCGAGCTAG  CAGCTTGCCAT  GCCTGCAGCA  GAAATGGTTG  AACTCCCGAG  AGTGTCCCTAC  ACCTAGGGGA
          TTCGAGCTAG  CCACGTGTAA  TTAAGTACTA  GCGCTCGATC  GTCCAGACGA  CGGAGCTCGT  CTTTACCAAC  TTGAGGCTC  TCACAGGATG  TGGATCCCT
          ^start of linker 1          ^end of linker 1          ^start of MMTV promoter

          styI          bsaJI          mwol
          tseI          fnu4HI/bsoFI          tseI          fnu4HI/bsoFI          mwol
          bbvI          bbvI          bbvI          bbvI          bbvI

          101  GAAGCAGCCA  AGGGTGTGTT  TCCACCAAG  GACGACCCGT  CTGGGCACAA  ACGGATGAGC  CCATCAGACA  AAGACATATT  CATTCTCTGC  TGCAAACTTG
          CTTCGTGGT  TCCCCAACAA  AGGGTGGTTC  CTGCTGGGCA  GAGCGTGTTC  TGCCTACTCG  GGTAGTCTGT  TTCTGTATAA  GTAAGAGACG  ACGTTTGAAC

          mwol          hgiJII          mboII
          cac8I          hgiJII          earI/xsp632I
          hgiAI/asphI          pleI      tru9I  sapi      mamI
          bsp1286          bmyI          hinfI      mseI  aluI      bsaBI
          bsiHKA1          bmyI          banII  hphI          CTCCTCTGTG  CAAGATTACA
          acil          bmyI          CTTTAAATAG  CTTTAAATAG  GAAATATTATC  GAGAGACAC  GTTCTAATGT
          aluI          CTTCAAGCC  CTTCAAGCC  CTTCAAGCC  GAGAGACAC  GTTCTAATGT
          CGTATCGAGA  CGAAACGACC  CCGTAACCCC  CTTCAAGCC  GAGAGACAC  GTTCTAATGT

```

FIG. 4

439

clai/bsp106  
 bspDI  
 sfanI  
 acilI taqI  
 fnu4HI/bsolI  
 mnlI  
 eco57I  
 301 ATCTAAACAA TTCGGAGAAC TCGACCTTCC TCTCCTGAGG CAAAGGACCAC AGCCAACATTC CTCTTACAAG CCGCATCGAT TTTGTCTTC AGAAATAGAA  
 TAGATTTTGT AAGCCTCTTG AGCTGGAAG AGAGGACTCC GTTCCTGGTG TCGGTTGAAG GAGAACTTC GCGTAGCTA AACAGGAAG TCTTTATCTT  
  
 tsp509I  
 taqI mnlI bsp36I/mstII/sauI  
 eco8II  
 401 ATAAGAATGC TTGCTAAAAA TTATATTTT ACCAATRAGA CCAATCCAAT AGGTAGATTA TTAGTTACTA TGTTAAGAAA TGAATCATT TCTTTTAGTA  
 TATCTTACG AACGATTTT AATATAAAAA TGCTTATCT GTTAGGTTA TCCATCTAAT AATCAATGAT ACAATCTTT ACTTAGTAAT AGAAAAATCAT  
  
 cac8I  
 bsmI  
 tsp509I  
 maelII mseI hinfI  
 501 CTATTTTAC TCAATTCAG AAGTTAGAAA TGGGAATAGA AAATAGAAAG AGACGCTCAA CCTCAATTGA AGAACAGGTG CAAGGACTAT TGACCACAGG  
 GATAAAAAATG AGTTAAGTC TTCAATCTTT ACCCTTATCT TTTATCTTCT TCTGCGAGTT GGAGTTAACT TCTGTCCAC GTTCTGATA ACTGGTGCTC  
  
 hgaI  
 esp3I  
 bsmBI  
 bsmAI  
 mnlI mboII  
 601 CCTAGAGTA AAAAAGGAA AAAAGAGTGT TTTGTCAA ATAGGAGACA GTTGGTGGCA ACCAGGACT TATAGGGGAC CTACATCTA CAGACCAACA  
 GGATCTTCAT TTTTCCCTT TTTTCTCACA AAAACAGTTT TATCTCTGT CCACCACCGT TGGTCCCTGA ATATCCCTCG GAATGTAGAT GTCTGTTGT  
  
 xmaI  
 maeI  
 bfaI  
 bsmFI  
 scrFI  
 mvaI  
 sau96I  
 avaiI  
 dsav  
 bstNI  
 bssKI  
 bsaJI  
 apyI  
 bsmFI  
 eco0109I/draII  
 nlaIV  
 ppuMI  
 701 GATGCCCCCT TACCATATAC AGGAAGATAT GACTTAAAT GGGATAGGTG GGTACAGTC AATGGCTATA AAGTGTTATA TAGATCCCTC CCITTTCCGT  
 CTACGGGGA ATGGTATATG TCCTTCTATA CTGAATTTAA CCTATCCAC CCAATGTCAG TTACCGATAT TTCACATAT ATCTAGGAG GGAAGAGCAC  
  
 mnlI  
 sau3AI  
 mboI/ndelII  
 dpnII  
 dpnI  
 alwI  
 bstVI/xhoII  
 801 GATGCCCCCT TACCATATAC AGGAAGATAT GACTTAAAT GGGATAGGTG GGTACAGTC AATGGCTATA AAGTGTTATA TAGATCCCTC CCITTTCCGT  
 CTACGGGGA ATGGTATATG TCCTTCTATA CTGAATTTAA CCTATCCAC CCAATGTCAG TTACCGATAT TTCACATAT ATCTAGGAG GGAAGAGCAC

rmaI                   styI                   nlaIII                   rmaI  
 maeI                   bsaJI                   rsaI                   maeI  
 bfaI                   mnlI                   csp6I                   bfaI                   bsmI  
 aluI                   bsmAI                   nlaIII  
 pleI                   801 AAAGACTCGC CAGAGCTAGA CCTCCTTGGT GTATGTTGTC TCAAGAAGAA AAAGACGACA TGAACAACA GGTACATGAT TATATTTATC TAGGAACAGG  
 hinfI                   TTTCTGACGG GTCTCGATCT GGAGGAACCA CATAACAACAG AGTTCCTCTT TTTCTGCTGT ACTTTGTTGT CCATGTACTA ATATAAATAG ATCCTTGTCC  
 tspRI  
 styI                   alwNI  
 bslI                   bsmFI  
 bslI bsaJI mnlI alw26I/bsmAI                   nlaIII  
 801 AATGCACATT TGGGGAAGA TTTTCCATAC CAAGGAGGGG ACAGTGGCTG GACTAATAGA ACATTATTCT GCAAAAACCTT ATGGCATGAG TTATTATGAA  
 TTACGTGAAA ACCCCTTTCT AAAGGTATG GTTCTCCTCCG TGTCAACCGAC CTGATTATCT TGTAAATAAGA CGTTTTTGAA TACCGTACTC AATAATACTT  
 tru9I  
 sau96I                   styI                   mseI                   fokI  
 haeIII/palI                   nlaIV                   smlI                   tru9I                   bstF5I  
 asuI                   aciI bsaJI aflII/bfrI                   maeIII                   mnlI                   bsmAI  
 1001 TAGCCTTTAT TGGCCCAACC TTGGGGTTCC CAAGCCTTAA GTAAGTTTTT GGTTCACAAAC TGTTCCTTAA ACAGAGGATGT GAGACAAGTG GTTTCCTGAC  
 ATCGGAATA ACCGGGTTGG AACGCCAAGG GTTCGGAAT CATTCAAAA CCAATGTTG ACAAGAATTT TGTCTCTACA CTCTGTTTAC CAAAGGACTG  
 sstI  
 sacI  
 hgiJII  
 hgiAI/aspHI  
 ecl136II  
 bsp1286  
 bsiHKA  
 bmyI  
 ddeI  
 sau3AI  
 mboI/ndelI  
 dpnII aluI                   tsp509I  
 dpnI banII ddeI                   apoI  
 1101 TTGGTTTGGT ATCAAAGGTT CTGATCTGAG CTCTGAGTGT TCTATTTTCC TATGTTCTTT TCGAATTTAT CCAAAATCTTA TGTAAATGCT TATGTAACCC  
 AACCAGAACCA TAGTTTCCAA GACTAGACTC GAGACTCACA AGATAAAGG ATACAAGAAA ACCTTAAATA GGTTTAGAAT ACATTTACGA ATACATTTGG

bsmAI  
 esp3I  
 foki bsmBI bsrBI tsp4SI  
 bstf5I acilI maeIII  
 1201 AAGATATAAA AGAGTGGCTGA TTTTTCAGT AACTTGCAA CAGTCCTAAC ATTACCTCT TGTGTGTTTG TGTCTGTTTC CCATCCCGTC TCCGCTCGTC  
 TTCTATATTT TCTCAGGACT AAAAAGCTCA TTTCAGGATTG GTAGTGAGA ACACACAAC ACAGACAAGC GGTAGGGCAG AGCGGAGCAG  
 mnlI  
 hphI  
 sau3AI  
 alwI  
 mspI  
 hpall  
 scrFI  
 nciI mboI/ndeII  
 dsav dpnII  
 cauII  
 ecoO109I/draII  
 mnlI bsmFI acilI  
 sau96I  
 nlaIV  
 avall  
 asuI  
 sanDI  
 ppuMI  
 nlaIV  
 fnu4HI/bsuFI  
 haefII/palI  
 mcrI  
 eagI/xmaIII/ecI XI  
 eaeI  
 notI  
 fnu4HI/bsuFI scfI  
 cac8I cfrI tru9I  
 aluI acilI acilI  
 pstI  
 mnlI  
 bspDI  
 nruI  
 bspDI  
 hindIII  
 bsiEI  
 mseI  
 bsgI  
 1301 ACTTATCCTT CACTTTCAG AGGTCCCC CGCAGACCCC GGATCGCTAG CTCGCGAATC GATAAGCTTG CGCGCGCTTA ACTCCAGAAG TTGGTCTGTA  
 TGAATAGGAA GTGAAGGTC TCCCAGGGGG CGGTCTGGGG CCTAGCGATC GAGCGCTTAG CTATTGCAAC GCCGGCGAAT TGACGTCTTC AACCAAGCACT  
 ^start of BS intron insert at Cla  
 ^bp820 in pCI  
 ^start of BS insert at HindIII  
 pleI  
 hinfI  
 mboII  
 bpuAI  
 bbsI  
 nlaIV  
 hgiCI  
 bsrI  
 bsmAI  
 taqI  
 bsrI  
 bsaI  
 mseI  
 maeIII  
 1401 GGCACTGGGC AGGTAAGTAT CAAGGTTACA AGACAGGTTT AAGGAGACCA ATAGAACTG GGCCTGTGCA GACAGAGAAG ACTCTTGGCT TTCTGATAGG  
 CCGTGACCGG TCCATTTCATA GTTCCAATGT TCTGTCCAAA TTCTCTGGT TATCTTIGAC CCGAACAGCT CTGTCTCTTC TGACAACGCA AAGACTATCC  
 ^start of chimeric intron at pCI 857

fnu4HI/bsoFI  
 mcrI  
 eagI/xmaIII/ecI XI  
 eaeI  
 cfrI  
 notI  
 fnu4HI/bsoFI  
 tru9I haeIII/palI tsp50  
 mseI bsiEI hindIII ecoRI  
 aluI smlI acil acil aluI taqI  
 tsp509I aflII/bfrI cac8I ecorV apoI  
 TTCATTACA GCCTTTAAGC GCCCGCAGC TTGATATCGA  
 AAGTTAATGT CGAGAAATTCG CCGCGGTTCG AACTATAGCT  
 ^end of chimeric intron at pCI 989  
 ^end of BS insert at HindIII^

scrFI  
 mvaI  
 ecorII  
 dsav  
 bstNI  
 bssKI  
 apyI  
 bslI bsaJI  
 bstF5I  
 foki  
 1501 CACCTATTGG TCTTACTGAC ATCCACTTTG CTTTCTCTC CACAGGTGTC  
 GTGGATAACC AGAATGACTG TAGGTGAAAC GGAAAGACAG GTGTCACAG  
 ^end of BS insert at HindIII^

hinPI  
 hhaI/cfoI  
 thaI  
 fnuDII/mvnI  
 bstUI  
 bsh1236I  
 mwOI sau96I  
 hinPI mspI  
 hhaI/cfoI  
 cac8I hpall  
 bssHII nlaIV  
 thaI scrFI  
 fnuDII/mvnI  
 mnlI bstUI nciI  
 xhoI bsh1236I haeIII/palI  
 smlI hinPI dsav  
 paerVI hhaI/cfoI asuI  
 aluI avai cac8I cauII  
 hindIII taqI bssHII bssKI  
 TTCTCGAGG CGCGGCCCG GCCCCACCC CTCGCAGCAC CCGCGCCCC  
 AAGAGCTCC CGCGCGGGC CGCGGTCTG GACCGTCTG GCGCGGGGG  
 ^end of BS intron insert at spe  
 ^start of human HER2 from BS at xhoI

scrFI  
 nciI  
 mspI  
 hpall  
 dsav  
 cauII  
 bssKI  
 bsaJI sau3AI  
 xmaI/pspAI  
 smaI mboI/ndeII sau3AI  
 scrFI dpnII mboI/ndeII  
 nciI dpnI  
 tsei dsav alwI  
 fnu4HI/bsoFI  
 bbvI cauII nlaIV maeI alwI  
 scrFI bssKI bstVI/xhoII bstVI/xhoII  
 pstI bsaJI bamHI bfaI bamHI  
 bsgI avai alwI speI alwI  
 1601 ATTCCTGCGAG CCGCGGGGAT CCACTAGTGG ATCCAAAGAA TTCAAAGAC  
 TAAGGACGTC GGGCCCCCTA GTGATCACC TAGGTTCTT AAGTTTTCG

9/39

10/39

hinPI  
 hhaI/cfoI  
 thal  
 fnuDII/mvni  
 bstUI  
 mwoI bshI236I mspi  
 hpaII mwoI  
 cfr10I/bsrFI  
 GCCTGCCACC CCTGTTCTCC GATGTGTAAG GGTCTCCCGT GCTGGGGAGA GAGTTCTGAG GATTGTGAGA GCCTGACGGC CACTGTCTGT GCCGGTGGCT  
 CGGACGGTGG GGACAAGAGG CTACACATTC CCGAGGGCCA CGACCCCTCT CTACAGACTC CTAACAGTCT CGGACTGGCG GTGACAGACA CGGCCACCGA  
 191 A C H P C S P M C K G S R C W G E S S E D C Q S L T R T V C A G G C  
  
 mspAII/nspBII  
 mwoI tseI  
 nlaIV fnu4HI/bsOFI  
 hgiJII bslI  
 bsp1286 bbvI  
 bmyI acII  
 banII bslI  
 mnlI alwNI hgaI  
 ddel alw26I/bsmAI tspRI  
 GCCTGCCACC CCTGTTCTCC GATGTGTAAG GGTCTCCCGT GCTGGGGAGA GAGTTCTGAG GATTGTGAGA GCCTGACGGC CACTGTCTGT GCCGGTGGCT  
 CGGACGGTGG GGACAAGAGG CTACACATTC CCGAGGGCCA CGACCCCTCT CTACAGACTC CTAACAGTCT CGGACTGGCG GTGACAGACA CGGCCACCGA  
 2301 A C H P C S P M C K G S R C W G E S S E D C Q S L T R T V C A G G C  
  
 cac8I  
 tseI  
 fnu4HI/bsOFI  
 mspAII/nspBII  
 bslI  
 acII  
 cac8I  
 bsp1286  
 bmyI bbvI nlaIV  
 GTGCCCCGTG CAAGGGGCA CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG  
 CACGGGCGAC GTTCCCGGT GACGGTGAC TGACGCGGT ACTCGTGACA CGACGGCCA CGTCCCGG GTTCGTGAGA CTGACGGACC GGACGGAGGT  
 2401 A R C K G P L P T D C C H E Q C A A G C T G P K H S D C L A C L H  
  
 tseI  
 fnu4HI/bsOFI  
 mspAII/nspBII  
 bslI  
 acII  
 cac8I  
 bsp1286  
 bmyI bbvI nlaIV  
 GTGCCCCGTG CAAGGGGCA CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG CTGCCACTG  
 CACGGGCGAC GTTCCCGGT GACGGTGAC TGACGCGGT ACTCGTGACA CGACGGCCA CGTCCCGG GTTCGTGAGA CTGACGGACC GGACGGAGGT  
 225 A R C K G P L P T D C C H E Q C A A G C T G P K H S D C L A C L H



12/39

13/39

sau96I  
 avaiI  
 asuI  
 nlaIV  
 scrFI  
 draIII mvaI  
 mwoI bsp1286 bsmFI  
 bstAPI bmyI ecorII  
 hgiAI/aspHI dsav  
 bsp1286 nlaIV bstNI  
 bsiHKAi hgiCI bssKI  
 bmyI bani bsaJI  
 apaII/snoI apyI  
 alw44I/snoI bsaJI aluI nlaIV aciI  
 sau96I foki  
 haeIII/pali  
 asuI bstf5I  
 mnII  
 ddel bsrI tspRI bsrI mnII  
 3101 ACTGAGGAA CTGGGCACTG GACTGGCCCT CATCCACCAT AACACCCACC TTGCTTCGT GCACACGGTG CCTGGGACC AGCTCTTTCG GAACCCGCAC  
 TGACTCCCTT GACCCGTCAC CTGACCGGGA GTAGGTGTA TTGTTGGTGG AGACGAGCA CGTGTGCCAC GGGACCCCTGG TCGAGAAAGC CTGGGCGTG  
 458 L R E L G S G L A L I H H N T H L C F V H T V P W D Q L F R N P H  
 sau96  
 pspOI  
 nlaI  
 hgiJ  
 bspI  
 bmyI  
 bani  
 scrFI  
 mvaI  
 ecorII  
 dsav  
 bstNI  
 bssKI  
 bsaJI  
 apyI  
 sau96I  
 avaiI asuI  
 asuI apaI  
 nlaIV ecoII  
 TGGGGTCCAG  
 GTTCGAGACG AGGTGTGACG GTTGCCCGT CTCTGTCTCA CACACCCGT CCCGACCGG ACGGTGTGTCG ACACCGGGC TCCGTGTGACG ACCCCAGGTC  
 491 Q A L L H T A N R P E D E C V G E G L A C H Q L C A R G H C W G P G  
 sequence change from Coussens to Yamamoto.  
 haeIII/pali  
 scrFI  
 mvaI  
 ecorII  
 dsav  
 bstNI  
 bssKI  
 apyI  
 haeIII/pali  
 sau96I  
 asuI haeI  
 aluI hinPI bmyI  
 pvuII hhaI/cfoI  
 mspAI/nspBI mnII tspRI  
 nlaIV ecoII  
 TGGGGTCCAG  
 GTTCGAGACG AGGTGTGACG GTTGCCCGT CTCTGTCTCA CACACCCGT CCCGACCGG ACGGTGTGTCG ACACCGGGC TCCGTGTGACG ACCCCAGGTC  
 491 Q A L L H T A N R P E D E C V G E G L A C H Q L C A R G H C W G P G  
 sequence change from Coussens to Yamamoto.  
 haeIII/pali  
 eaeI  
 cfrI  
 mspi  
 hpaII  
 bslI mnII  
 cfr10I/bsrFI  
 aluI  
 tspRI  
 TCCACACTGC CAACCGGCA GAGGACGAGT GTGTGGCGA GGGCTGGCC TCCACACGAG TGTGGCCCG AGGCACATGC TGGGGTCCAG  
 3201 CAAGCTCTGC  
 GTTCGAGACG AGGTGTGACG GTTGCCCGT CTCTGTCTCA CACACCCGT CCCGACCGG ACGGTGTGTCG ACACCGGGC TCCGTGTGACG ACCCCAGGTC  
 491 Q A L L H T A N R P E D E C V G E G L A C H Q L C A R G H C W G P G  
 sequence change from Coussens to Yamamoto.

15/39

16/39

3801 CTCCAGGAAA CGGAGCTGGT GGAGCCGCTG ACACCTAGCG GAGCGATGCC CAACCCAGCG CAGATCCGGA TCCTGAAAGA GACGGAGCTG AGGAAGGTGA  
 GACGTCCTTT GCCTCAGCCA CCTCGCGGAC TGTGGATCGC CTCGATACGG GTTGGTCCGC GTCTACGCTT AGGACTTTCT TCCTCTCGAC TCCTTCCACT  
 691 L Q E T E L V E P L T P S G A M P N Q A Q M R I L K E T E L R K V K

3901 AGGTGCTGG ATCTGGCGCT TTGGGCACAG TCTACAAGGG CATCTGGATC CCTGATGGGG AGAATGTGAA AATCCAGTG GCATCAAG TGTGAGGGA  
 TTCACGAACC TAGACCGCGA AAACCGTGTG AGATGTTCCC GTAGACCTAG GCACTACCCC TCTTACACTT TTAAGGTGAC CGTAGTTTC ACACTCCCT  
 725 V L G S G A F G T V Y K G I W I P D G E N V K I P V A I K V L R E

4001 AAACACATCC CCCAAGCCA ACAAGAAAT CTTAGAGGAA GCATACGTGA TGGCTGGTGT GGGCTCCCCA TATGTCTCCC GCCTTCTGG CATCTGCCTG  
 TTTGTAGG GGGTTTCGGT TGTTCCTTA GAATCTGCTT CGTATGCACT ACCGACACA CCCGAGGGGT ATACAGAGGG CGGAACACC GTAGACGGAC  
 758 N T S P K A N K E I L D E A Y V M A G V G S P Y V S R L L G I C L

Restriction Enzymes:
   
 hinfI mboI/ndeII
   
 hhaI/cfoI dpnII
   
 scrFI nlaIV
   
 mvaI bstYI/xhoII
   
 ecoRII bamHI
   
 dsav aciI
   
 bstNI sfanI dpnI esp3I mnlI
   
 bssKI mami alwI bsmBI ddeI
   
 apyI bsabI alwI bsmAI aluI hphI
   
 sau3AI
   
 mspAII/nspBII
   
 rmaI
   
 aciI maeI
   
 fnu4HI/bsaFI aciI
   
 nlaIV bfaI
   
 mwOI
   
 aluI
   
 bstYI/xhoII
   
 bstYI/xhoII
   
 alwI haeII
   
 accI sfanI alwI
   
 bstYI/xhoII
   
 bamHI
   
 mscI/balI
   
 haeI
   
 eaeI
   
 tspRI
   
 tsp509I cfrI mslI
   
 apoI bsrI haeII/palI mnlI
   
 nlaIV
   
 hgiIII
   
 bspI286
   
 bmyI
   
 banII ndeI bsmAI bglI sfanI
   
 tail
   
 maeII
   
 bsaAI
   
 ddeI
   
 foki
   
 bstF5I

17/39

18/39

mspI  
 hpaII  
 naeI/ngoMI  
 cfr10I/bsrFI  
 cac8I  
 sgrAI  
 bpmI/gsuI  
 hinfI  
 4401 CTGGAGTCCA TTCTCCGCG CGGTTCCACC CACCAGAGTG ATGTGTGGAG TTATGGTGTG ACTGTGTGGG AGCTGATGAC TTTTGGGGCC AAACCTTACG  
 891 L E S I L R R R R F T H Q S D V W S Y G V T V W E L M T F G A K P Y D  
 haeIII/palI  
 sau96I  
 asuI  
 nlaIV  
 bslI  
 tsp45I  
 maeIII  
 aluI  
 4501 ATGGGATCCC AGCCCGGGAG ATCCCTGACC TGCTGGAAAA GGGGAGCGG CTGCCCCAGC CCCCACATCG CACCATTGAT GTCTACATGA TCATGGTCAA  
 TACCCTAGGG TCGGGCCCTC TAGGACTGG ACGACCTTTT CCCCCTGCC GACGGGTGCG GGGGGTAGAC GTGGTAACTA CAGATGTACT AGTACCAGTT  
 925 G I P A R E I P D L L E K G E R L P Q P P I C T I D V Y M I M V K  
 scrFI  
 nciI  
 mspI  
 hpaII  
 dsav  
 cauiI  
 bssKI  
 xmaI/pspAI  
 bslI smaI  
 sau3AI scrFI  
 mboI/ndelI  
 dpnII nciI  
 dpnI dsav sau3AI  
 alwI cauII mboI/ndelI  
 nlaIV bssKI dpnII  
 bstYI/xhoII dpnI  
 bamHI bsaJI alwI bspMI  
 alwI avai bstYI/xhoII bsrBI  
 4501 ATGGGATCCC AGCCCGGGAG ATCCCTGACC TGCTGGAAAA GGGGAGCGG CTGCCCCAGC CCCCACATCG CACCATTGAT GTCTACATGA TCATGGTCAA  
 TACCCTAGGG TCGGGCCCTC TAGGACTGG ACGACCTTTT CCCCCTGCC GACGGGTGCG GGGGGTAGAC GTGGTAACTA CAGATGTACT AGTACCAGTT  
 925 G I P A R E I P D L L E K G E R L P Q P P I C T I D V Y M I M V K  
 tseI  
 mwoI  
 fnu4HI/bsoFI  
 bbvI  
 fnu4HI/bsoFI  
 aciI  
 bsrBI  
 sau3AI  
 mboI/ndelI  
 dpnII  
 dpnI  
 bclI  
 nlaIII  
 accI mslI nlaIII

19/39



20/39

[illegible]

21/39

sau96I  
 nlaIV  
 avaII  
 rsal  
 asuI  
 csp6I mnlI  
 rsal  
 csp6I  
 scfI acII tspRI ppumI  
 mnlI mspAI/nspBI eco0109I/draII  
 mnlI bsmAI  
 5001 GGAATGGGG CAGCCAAGG GCTGCAAGC CTCCCCAC ATGACCCAG CCTCTACAG CGGTACAGT AGACCCAC AGTACCCCTG CCCTCTGAGA  
 CCTTACCCC GTCGTTTCC CGACGTTTCG GAGGGTGTG TACTGGGTG GAGAGATGC GCATGTCAC TCCGCGGTG TCATGGGAC GGGAGACTCT  
 1091 G M G A A K G L Q S L P T H D P S P L Q R Y S E D P T V P L P S E T  
 tsel styI tsel  
 fnu4HI/bsoFI fnu4HI/bsoFI  
 bbvI bsaJI bbvI mnlI  
 nlaIII  
 5001 GGAATGGGG CAGCCAAGG GCTGCAAGC CTCCCCAC ATGACCCAG CCTCTACAG CGGTACAGT AGACCCAC AGTACCCCTG CCCTCTGAGA  
 CCTTACCCC GTCGTTTCC CGACGTTTCG GAGGGTGTG TACTGGGTG GAGAGATGC GCATGTCAC TCCGCGGTG TCATGGGAC GGGAGACTCT  
 1091 G M G A A K G L Q S L P T H D P S P L Q R Y S E D P T V P L P S E T  
 tsel  
 fnu4HI/bsoFI  
 bbvI  
 scfI  
 pstI  
 bsgI  
 bspMI  
 tail  
 maelI  
 sau96I  
 nlaIV  
 haeIII/palI  
 asuI mwoI  
 avai eco0109I/draII  
 bslI mnlI  
 5101 CTGATGGCTA CTTTGGCCC CTGACTTGA GCGCCAGCC TGAATATGTG AACAGCCAG ATGTTGGCC CCAGCCCTC TCGCCCGGAG AGGCCCTCT  
 GACTACCGAT GCAACGGGG GACTGGACGT CGGGGTGCG ACTTATAC TGTGTCGTC TACAAGCCG GGTGCGGGA AGCGGGCTC TCCCGGGAGA  
 1125 D G Y V A P L T C S P Q P E Y V N Q P D V R P Q P P S P R E G P L  
 scrFI  
 mval  
 ecorII  
 dsav  
 bstNI  
 bssKI  
 bsaJI  
 apyI  
 tail  
 maelI  
 haeIII/palI  
 sau96I pleI  
 asuI hinfI  
 bsaJI mboII  
 5201 GCCTGCTGCC CGACCTGCTG GTGCCACTCT GGAAGGGCC AACACTCTCT CCCCAGGAA GAATGGGTG GTCAAGACG TTTTGGCTT TGGGGGTGCC  
 CGGACGACG GCTGGACGAC CACGGTGAGA CCTTCCCGG TTCTGAGA GGGGTCCCT CTTACCCAG CAGTTTCTG AAAACGGAA ACCCCACGG  
 1158 P A A R P A G A T L E R A K T L S P G K N G V V K D V F A F G G A  
 dsaI  
 bsaJI  
 nlaIV  
 hgiCI  
 banI

23/39

24/35

```

mspI      mspI
hpaII     hpaII
scrFI     scrFI
ncII      ncII
dsav      dsav
cauII     cauII
bskKI     bskKI
bsII      bsII
tseI      tseI
bsII      bsII
fnu4HI/bsoFI
fnu4HI/bsoFI
mboII     mboII
bsaJI     bsaJI
bsrI      bsrI
bgIII     bgIII
bstYI/xhoII
scfI      scfI
taqI      taqI
5701 AGGACCTAGA GGAAGGCATC CAAACGGTGA TGGGAGGCT GGAAGATGCG AGCCGCCGGA CTGGGCACAT CTTCAAGCAG ACCTACAGCA AGTCGACAC
TCCTGGATCT CCTCCGTTAG GTTTGGGACT ACCCTCCGA CCTTCTACCG TCGGGGGCCT GACCCGTCTA GAAGTTGGTC TGGATGCTGT TCAAGCTGTG
*end of ex 4/ start ex 5

xmaI      xmaI
maeI      maeI
bfaI      bfaI
sau96I    sau96I
avaII     avaII
asuI      asuI
ppuMI     ppuMI
mnlI      mnlI
ecoO109I/draII
sfaNI     sfaNI
foki      foki
bstF5I    bstF5I
mboII     mboII
bbvI      bbvI
fnu4HI/bsoFI
fnu4HI/bsoFI
tseI      tseI
mboII     mboII
bsaJI     bsaJI
bsrI      bsrI
bgIII     bgIII
bstYI/xhoII
scfI      scfI
taqI      taqI
5801 AAACACAC AACGATGACG CACTACTCAA GAACACGGG CTGCTCTACT GCTTCAGGAA GGACATGGAC AAGGTGAGA CATTCTGCG CATCGTCAG
TTTGACTGTG TTGCTACTGC GTGATGAGTT CTTGATGCCC GACGAGATGA CGAAGTCCTT CCTGTACCTG TTCCAGCTCT GTAAGGACCC GTAGCAGTC

```

24/39

```

bslI
sau96I
haeIII/palI
asul
sau96I
pspOMI/bsp120I
nlaIV
hgiIII
bsp1286
bmyI
banII
asul
apaI
nlaIV
eco109I/draII bbsI
GGGCCCCAAG TTGGGAAGAC AACCTGTAGG GCCTGCGGGG TCTATTGGG AACCAAGCTG GAGTGAGTG GCACAATCTT GGCTCACTGC AATCTCCGCC
CCCGGGTTC AACCTTCTG TTGGACATCC CGGACGCCCC AGATAGCCC TTGTTTCAC CTCACGTCAC CGTGTAGAA CCGAGTGACG TTAGAGCGCG
610I

cac8I
haeIII/palI
sau96I
eco109I/draII
scfI asuI acilI
nlaIV aluI tspRI
bpmI/gsuI
mwolI bslI
acilI
620I

sphi
nspHI
nspi
scrFI mval
scrFI mval
mval ecorII
ecorII dsav
dsav nlaIII cellI/espi
bstNI ppul10I bstNI
bssKI nsiI/avaIII bIpI/bpul102I
tfII apyI nlaIII bssKI aluI
hinFI cac8I apyI ddeI tsp509I
esp3I bsmBI bsmAI
TCCGTGGTTC AAGCGATTCT CCTGCTCAG CCTCCCGAGT TGTGGGATT CCAGGCATGC ATGACCAGGC TCAGCTAATT TTGTTTTTTT TGGTAGAGAC
AGACCCCAAG TTCGCTAAGA GGACGGATC GGAGGGTCA ACAACCTAA GTCCCGTACG TACTGGTCCG AGTCGATTAA AACAAAAA ACCATCTCTG

```

27/39



```

scrFI
mvaI
ecorII
dsv
bstNI
bssKI
apyI
    haeIII/palI
msci/balI
    haeI
    eaeI
    cfrI
        hphI
            hphI
                haeI
                    mboI/ndeII
                        sau3AI
                            mboI/ndeII
                                dpnII
                                    hphI
                                        haeI
                                            bstXI
                                                styI haeIII/palI
                                                    bsaJI mnlI
                                                        tsp509I
                                                            6301 GGGGTTTCAC CATATTGGCC AGGCTGGTCT CCAACTCCTA ATCTCAGGTG ATCTACCCAC CTTGGCCTCC CAATTGGTG GGAATTACAGG CGTAGACCAC
                                                                CCCCRAAGTG GTATAACCGG TCCGACCAGA GGTGAGGAT TAGAGTCCAC TAGATGGGTG GAACCGGAGG GTTACCGAC CTAATGTCC GCACCTGGTG
                                                                    tspRI
mspi
cfr10I/bsrFI
bsaWI
    styI sau96I hpaII
        ncoI haeIII/palI
            dsal asuI ageI
                bsaJI pflMI
                    bspMI nlaIII bslI
                        bsmFI
                            6401 TGCTCCCTTC CCTGTCCCTC TGATTTTAAA ATAACTATAC CAGCAGGAGG ACCTCCAGAC ACAGCATAGG CTACCTGCCA TGCCCCAACC GGTGGACAT
                                ACGAGGGAAG GGACAGGAAG ACTAAATTT TATTGATATG GTCGTCTCC TCCAGGTCTG TGTCGTATCC GATGACGGT ACCGGGTGG CCACCTGTA
                                    hgiAI/aspHI
                                        sau3AI
                                            mboI/ndeII
                                                dpnII bsp1286
                                                    dpnI bsiHKA1
                                                        tsp509I
                                                            pvuI/bspcI
                                                                mscI
                                                                    nlaIII
                                                                        mcrI bmyI
                                                                            ael/asnI/vspI
                                                                                bsiEI
                                                                                    apaLI/snoI
                                                                                        rcaI apoI
                                                                                            6501 TTGAGTTGCT TGCTTGGCAC TGTCCTCTCA TCGGTTGGGT CCACTCAGTA GATGCCCTGT GAATTACGAT CGGTGCACAT TAATTCATGA AATTCGTAAT
                                                                                                AACTCAACGA ACGAACCGTG ACAGGAGAGT ACCCAACCA GGTGAGTCAT CTACGGACA CTTAATGCTA GCCACGTGA ATTAAGTACT TTAAGCATTA
                                                                                                    ^start of linker 2
                                                                                                        ^end of linker

```

29/39

Restriction Enzyme	Sequence
6901	CGGTAAATACG GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGACATG TGACCAAAAG GCCAGCAAAA GGCACAGGAAC CGTAAAAAGG CCGCGTTGCT GCCATTATGC CAATAGGTCT CTATGTCCTC TATTCGCTCC TATTCGCTCC TTTCTGTAC ACTCGTTTC CGTCTGTTT CCGTCTCTG GCATTTTCC GCGCAACGA
7001	GGCGTTTTTC CATAGGCTCC GCGCCCTCTG AAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGCGCA AACCGACAG GACTATAAAG ATACACAGCG CCGCAAAAAG GTATCCGAGG CCGGGGACT GCTCGTAGTG TTTTACGTG CGAGTTCAGT CTCCACCGCT TTGGCTGTC CTGATATTC TATGCTCCOC
7101	TTTCCCCCTG GAAGTCCCT CGTGGCTCT CCGTTGCCG CCGTGTCCG GACACCGGCA GGCACCGGCA GGCACCGGCA GGCACCGGCA GGCACCGGCA AAAGGGGAC CTTGAGGGA GCACCGGCA GGCACCGGCA GGCACCGGCA GGCACCGGCA GGCACCGGCA GGCACCGGCA GGCACCGGCA GGCACCGGCA
7201	AATGCTCAG CTGTAGGTAT CTCAGTTCG TGTAGTCTG TCGCTCCAG CTGGGCTGTG TGCACGAACC CCGCGTTTAC CCCGACCGT GCGCTTATC TTACGAGTGC GACATCCATA GAGTCAAGC ACATCCAGC AGCGAGTTC GACCCGACAC ACGTCTTG GGGCAAGTC GGGCTGGCA CCGGGAATAG

31/39

tru9I nlaIV  
 tsp509I hgiCI  
 tru9I mnlI  
 mseI mnlI  
 ahaIII/draI maeIII mnlI  
 7701 CTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAAT CAGTGAGGCA CCTATCTCAG  
 GAAATTTTAA TTTTACTTC AAAATTTAGT TAGATTTCAT ATATACTCAT TTGAACCCAGA CTGTCAATGG TTACGAATTA GTCACTCCGT GGATAGAGTC  
 bsrI tseI  
 sau96I fnu4HI/bsoFI  
 nlaIV bbvI  
 haeIII/palI  
 asuI tspRI bsrDI  
 7801 CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCGTACTCCC CGTGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT GCCCCCAGTG CTGCAATGAT  
 GCTAGACAGA TAAAGCAAGT AGGTATCAAC GCACTGAGGG GCAGCACATC TATTGATGCT ATGCCCTCC ATGCTGCTAG CCGGGGTAC GACGTTACTA  
 bsmAI  
 bsaI  
 thai  
 fnuDII/mvni mspI bpmI/gsuI  
 bstVI hpaII mwoI haeIII/palI sau96I foki  
 bsh1236I cfr10I/bsrFI bgII sau96I hinPI avall mnlI  
 aciI hphI nlaIV cac8I hpaII asuI hhaI/cfoI asuI aciI bstF  
 7901 ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA ATAAACCAGC CAGCCGGAAG GCGCGAGCGC AGAAGTGGTCT CTGCAACTTT ATCCGCTCC  
 TGGCGCTCTG GGTGCGAGTG GCCGAGGTCT AAATAGTCTT TATTGGTCTG GTGGCTTC CCGGCTCGG TCTTACCAG GACGTTGAAA TAGGGGAGG  
 scrFI  
 nciI  
 mspI  
 hpaII  
 tsp509I dsav rmaI  
 tru9I caulI maeI  
 msel bssKI bfaI  
 bsrI aseI/asnI/vspI aluI  
 8001 ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTTG CCAACGTTG TTGCCATTGC TGCTGGCATC GTGGTGTAC  
 TAGGTCAGAT AATTAACAAC GGCCTTCGA TCTCATTCTA CAAGCGTCA ATTATCAAC GCGTTGCAAC AACGGTAAAC ACGACCGTAG CACCACAGTG  
 tseI mslI  
 fnu4HI/bsoFI  
 bsrDI cac8I  
 mwoI bbvI sfanI  
 tsp45I  
 maeIII

33/39

34/39

35/39



3639


5  
FIGURE 1

FIG. 5

37/39

## Variable Heavy Domain

		10	20	30	40
2C4	EVQLQQSGPELVKPGTSVKISCKAS	[GFTFTD	YTM	D]	WVKQS
	*** ** *	*** *			**
574	EVQLVESGGGLVQPGGSLRLSCAAS	[GFTFTD	YTM	D]	WVRQA
			*** ** *		
hum III	EVQLVESGGGLVQPGGSLRLSCAAS	[GFTFSS	YAMS	]	WVRQA
		50 a	60	70	80
2C4	HGKSLEWIG	[DVNPNSGG	SIYNQRFKG]	KASLTVDRSS	RIVYM
	* * **			*** *	*** *
574	PGKGLEWVA	[DVNPNSGG	SIYNQRFKG]	RFTLSVDRS	KNTLYL
		***** ** *		* * *	
hum III	PGKGLEWVA	[VISGDGG	STYYADSVKG]	RFTISRDN	SKNTLYL
	abc	90	100ab	110	
2C4	ELRSLTFEDTAVYYCAR	[NLGPSFYFDY]	WGQGTTLTVSS		
	*** **			**	
574	QMNSLRAEDTAVYYCAR	[NLGPSFYFDY]	WGQGTTLTVSS		
		*****			
hum III	QMNSLRAEDTAVYYCAR	[GRVGYS	LDY]	WGQGTTLTVSS	

FIG. 6


38/39

## Variable Light Domain

	10	20	30	40
2C4	DTVMTQSHKIMSTSVGDRVSITC	[KASQDV SIGVA]	WYQQRP	
	**      ***** *	*	*	
574	DIQMTQSPSSLSASVGDRVTITC	[KASQDV SIGVA]	WYQQKP	
		*      ** ***		
hum κI	DIQMTQSPSSLSASVGDRVTITC	[RASQIS NYLA]	WYQQKP	
	50	60	70	80
2C4	GQSPKLLIY [SASYRYT]	GVPDRFTGSGSGTDFTFTISSVQA		
	**	* *	* *	*
574	GKAPKLLIY [SASYRYT]	GVPSRFSGSGSGTDFTLTISLQP		
	* *****			
hum κI	GKAPKLLIY [AASSLES]	GVPSRFSGSGSGTDFTLTISLQP		
	90	100		
2C4	EDLAVYYC [QQYYIYPYT]	FGGGTKLEIKRT		
	* *	* *		
574	EDFATYYC [QQYYIYPYT]	FGQGTKVEIKRT		
	*** *			
hum κI	EDFATYYC [QQYNSLPWT]	FGQGTKVEIKRT		

FIG. 7

## Maytansinoids (DM1)



1. 623

FIG. 1

FIGURE 2





FIG 2







5/59

6/55

22

02624-1

2025-05-27 15:21:11

12

start of chemicl inon is 957



9/39

10/35

1139





13/34

14439

1539

16/39





19/35

[illegible]





[illegible]

22435

19561  
 19562  
 19563  
 19564  
 19565  
 19566  
 19567  
 19568  
 19569  
 19570  
 19571  
 19572  
 19573  
 19574  
 19575  
 19576  
 19577  
 19578  
 19579  
 19580  
 19581  
 19582  
 19583  
 19584  
 19585  
 19586  
 19587  
 19588  
 19589  
 19590  
 19591  
 19592  
 19593  
 19594  
 19595  
 19596  
 19597  
 19598  
 19599  
 19600  
 19601  
 19602  
 19603  
 19604  
 19605  
 19606  
 19607  
 19608  
 19609  
 19610  
 19611  
 19612  
 19613  
 19614  
 19615  
 19616  
 19617  
 19618  
 19619  
 19620  
 19621  
 19622  
 19623  
 19624  
 19625  
 19626  
 19627  
 19628  
 19629  
 19630  
 19631  
 19632  
 19633  
 19634  
 19635  
 19636  
 19637  
 19638  
 19639  
 19640  
 19641  
 19642  
 19643  
 19644  
 19645  
 19646  
 19647  
 19648  
 19649  
 19650  
 19651  
 19652  
 19653  
 19654  
 19655  
 19656  
 19657  
 19658  
 19659  
 19660  
 19661  
 19662  
 19663  
 19664  
 19665  
 19666  
 19667  
 19668  
 19669  
 19670  
 19671  
 19672  
 19673  
 19674  
 19675  
 19676  
 19677  
 19678  
 19679  
 19680  
 19681  
 19682  
 19683  
 19684  
 19685  
 19686  
 19687  
 19688  
 19689  
 19690  
 19691  
 19692  
 19693  
 19694  
 19695  
 19696  
 19697  
 19698  
 19699  
 19700  
 19701  
 19702  
 19703  
 19704  
 19705  
 19706  
 19707  
 19708  
 19709  
 19710  
 19711  
 19712  
 19713  
 19714  
 19715  
 19716  
 19717  
 19718  
 19719  
 19720  
 19721  
 19722  
 19723  
 19724  
 19725  
 19726  
 19727  
 19728  
 19729  
 19730  
 19731  
 19732  
 19733  
 19734  
 19735  
 19736  
 19737  
 19738  
 19739  
 19740  
 19741  
 19742  
 19743  
 19744  
 19745  
 19746  
 19747  
 19748  
 19749  
 19750  
 19751  
 19752  
 19753  
 19754  
 19755  
 19756  
 19757  
 19758  
 19759  
 19760  
 19761  
 19762  
 19763  
 19764  
 19765  
 19766  
 19767  
 19768  
 19769  
 19770  
 19771  
 19772  
 19773  
 19774  
 19775  
 19776  
 19777  
 19778  
 19779  
 19780  
 19781  
 19782  
 19783  
 19784  
 19785  
 19786  
 19787  
 19788  
 19789  
 19790  
 19791  
 19792  
 19793  
 19794  
 19795  
 19796  
 19797  
 19798  
 19799  
 19800  
 19801  
 19802  
 19803  
 19804  
 19805  
 19806  
 19807  
 19808  
 19809  
 19810  
 19811  
 19812  
 19813  
 19814  
 19815  
 19816  
 19817  
 19818  
 19819  
 19820  
 19821  
 19822  
 19823  
 19824  
 19825  
 19826  
 19827  
 19828  
 19829  
 19830  
 19831  
 19832  
 19833  
 19834  
 19835  
 19836  
 19837  
 19838  
 19839  
 19840  
 19841  
 19842  
 19843  
 19844  
 19845  
 19846  
 19847  
 19848  
 19849  
 19850  
 19851  
 19852  
 19853  
 19854  
 19855  
 19856  
 19857  
 19858  
 19859  
 19860  
 19861  
 19862  
 19863  
 19864  
 19865  
 19866  
 19867  
 19868  
 19869  
 19870  
 19871  
 19872  
 19873  
 19874  
 19875  
 19876  
 19877  
 19878  
 19879  
 19880  
 19881  
 19882  
 19883  
 19884  
 19885  
 19886  
 19887  
 19888  
 19889  
 19890  
 19891  
 19892  
 19893  
 19894  
 19895  
 19896  
 19897  
 19898  
 19899  
 19900  
 19901  
 19902  
 19903  
 19904  
 19905  
 19906  
 19907  
 19908  
 19909  
 19910  
 19911  
 19912  
 19913  
 19914  
 19915  
 19916  
 19917  
 19918  
 19919  
 19920  
 19921  
 19922  
 19923  
 19924  
 19925  
 19926  
 19927  
 19928  
 19929  
 19930  
 19931  
 19932  
 19933  
 19934  
 19935  
 19936  
 19937  
 19938  
 19939  
 19940  
 19941  
 19942  
 19943  
 19944  
 19945  
 19946  
 19947  
 19948  
 19949  
 19950  
 19951  
 19952  
 19953  
 19954  
 19955  
 19956  
 19957  
 19958  
 19959  
 19960  
 19961  
 19962  
 19963  
 19964  
 19965  
 19966  
 19967  
 19968  
 19969  
 1

INSDOCID: &lt;WO\_\_0100244A2TI\_&gt;

25/35

James M. Smith

[illegible]

24/35

[illegible]

27/39

28/39



27/35

```

      80:  GGGGATTTTC CATAGGCTCC GGGGCGGCTC CCGAGCTCAC AAGAAATCCG GCTCAGACTA GAGGNGGCCA AAGCGGACAG GAGCATAAAG ATACGAGGCG
      GCGCAAAAG GTATCTTAAAG CCGGGGCGACT GCTCGTCACTG TTTTNGGCG CAGATTGAGT GTCCGACCGG TGGGGCTGTC CAGATGATTC TATGCTGCGC
      curFI
      mvsl
      eocNAZ
      dsav
      bsbmC
      bsbmI
      bsbmI
      apyl
      acil
      clary
      bsbI
      dscl
      tagl
      smli
      wcli

```

[illegible]

31/35

34/39

8401 CAGTACAGC AACATTAGAA GTGCTGCTCA TGTGAAAGG VCTTGCGG CAGAACTCT CAGAGTATT ACCTGTTTG AGATCAGT CAGTGTACCC  
GCTGATGTC TGTGATTT CACAGTAT AACCTTGC AAGAGGCC GCTTTTGA GTCTAGAA TGTGACAGC TCTAGTGA GTGATGTC

34/37

8901 ACAGCTTATC TGTATACGGA TCCCGGAGC AGAAGAGTCC GTGAGGCGGT GTTGGGCGGT GTTGGGCGGT GTTGGGCGGT AGGAGTACAC CAGTACAGTA  
 TGTGAGACAG ACATTGCGT AGGAGCGTCC TCTGTTGCG TACTTTCGCG TACTTTCGCG TACTTTCGCG TACTTTCGCG TACTTTCGCG TACTTTCGCG  
 9001  
 9101  
 9201  
 9301  
 9401  
 9501  
 9601  
 9701  
 9801  
 9901  
 1001  
 1011  
 1021  
 1031  
 1041  
 1051  
 1061  
 1071  
 1081  
 1091  
 1101  
 1111  
 1121  
 1131  
 1141  
 1151  
 1161  
 1171  
 1181  
 1191  
 1201  
 1211  
 1221  
 1231  
 1241  
 1251  
 1261  
 1271  
 1281  
 1291  
 1301  
 1311  
 1321  
 1331  
 1341  
 1351  
 1361  
 1371  
 1381  
 1391  
 1401  
 1411  
 1421  
 1431  
 1441  
 1451  
 1461  
 1471  
 1481  
 1491  
 1501  
 1511  
 1521  
 1531  
 1541  
 1551  
 1561  
 1571  
 1581  
 1591  
 1601  
 1611  
 1621  
 1631  
 1641  
 1651  
 1661  
 1671  
 1681  
 1691  
 1701  
 1711  
 1721  
 1731  
 1741  
 1751  
 1761  
 1771  
 1781  
 1791  
 1801  
 1811  
 1821  
 1831  
 1841  
 1851  
 1861  
 1871  
 1881  
 1891  
 1901  
 1911  
 1921  
 1931  
 1941  
 1951  
 1961  
 1971  
 1981  
 1991  
 2001  
 2011  
 2021  
 2031  
 2041  
 2051  
 2061  
 2071  
 2081  
 2091  
 2101  
 2111  
 2121  
 2131  
 2141  
 2151  
 2161  
 2171  
 2181  
 2191  
 2201  
 2211  
 2221  
 2231  
 2241  
 2251  
 2261  
 2271  
 2281  
 2291  
 2301  
 2311  
 2321  
 2331  
 2341  
 2351  
 2361  
 2371  
 2381  
 2391  
 2401  
 2411  
 2421  
 2431  
 2441  
 2451  
 2461  
 2471  
 2481  
 2491  
 2501  
 2511  
 2521  
 2531  
 2541  
 2551  
 2561  
 2571  
 2581  
 2591  
 2601  
 2611  
 2621  
 2631  
 2641  
 2651  
 2661  
 2671  
 2681  
 2691  
 2701  
 2711  
 2721  
 2731  
 2741  
 2751  
 2761  
 2771  
 2781  
 2791  
 2801  
 2811  
 2821  
 2831  
 2841  
 2851  
 2861  
 2871  
 2881  
 2891  
 2901  
 2911  
 2921  
 2931  
 2941  
 2951  
 2961  
 2971  
 2981  
 2991  
 3001  
 3011  
 3021  
 3031  
 3041  
 3051  
 3061  
 3071  
 3081  
 3091  
 3101  
 3111  
 3121  
 3131  
 3141  
 3151  
 3161  
 3171  
 3181  
 3191  
 3201  
 3211  
 3221  
 3231  
 3241  
 3251  
 3261  
 3271  
 3281  
 3291  
 3301  
 3311  
 3321  
 3331  
 3341  
 3351  
 3361  
 3371  
 3381  
 3391  
 3401  
 3411  
 3421  
 3431  
 3441  
 3451  
 3461  
 3471  
 3481  
 3491  
 3501  
 3511  
 3521  
 3531  
 3541  
 3551  
 3561  
 3571  
 3581  
 3591  
 3601  
 3611  
 3621  
 3631  
 3641  
 3651  
 3661  
 3671  
 3681  
 3691  
 3701  
 3711  
 3721  
 3731  
 3741  
 3751  
 3761  
 3771  
 3781  
 3791  
 3801  
 3811  
 3821  
 3831  
 3841  
 3851  
 3861  
 3871  
 3881  
 3891  
 3901  
 3911  
 3921  
 3931  
 3941  
 3951  
 3961  
 3971  
 3981  
 3991  
 4001  
 4011  
 4021  
 4031  
 4041  
 4051  
 4061  
 4071  
 4081  
 4091  
 4101  
 4111  
 4121  
 4131  
 4141  
 4151  
 4161  
 4171  
 4181  
 4191  
 4201  
 4211  
 4221  
 4231  
 4241  
 4251  
 4261  
 4271  
 4281  
 4291  
 4301  
 4311  
 4321  
 4331  
 4341  
 4351  
 4361  
 4371  
 4381  
 4391  
 4401  
 4411  
 4421  
 4431  
 4441  
 4451  
 4461  
 4471  
 4481  
 4491  
 4501  
 4511  
 4521  
 4531  
 4541  
 4551  
 4561  
 4571  
 4581  
 4591  
 4601  
 4611  
 4621  
 4631  
 4641  
 4651  
 4661  
 4671  
 4681  
 4691  
 4701  
 4711  
 4721  
 4731  
 4741  
 4751  
 4761  
 4771  
 4781  
 4791  
 4801  
 4811  
 4821  
 4831  
 4841  
 4851  
 4861  
 4871  
 4881  
 4891  
 4901  
 4911  
 4921  
 4931  
 4941  
 4951  
 4961  
 4971  
 4981  
 4991  
 5001  
 5011  
 5021  
 5031  
 5041  
 5051  
 5061  
 5071  
 5081  
 5091  
 5101  
 5111  
 5121  
 5131  
 5141  
 5151  
 5161  
 5171  
 5181  
 5191  
 5201  
 5211  
 5221  
 5231  
 5241  
 5251  
 5261  
 5271  
 5281  
 5291  
 5301  
 5311  
 5321  
 5331  
 5341  
 5351  
 5361  
 5371  
 5381  
 5391  
 5401  
 5411  
 5421  
 5431  
 5441  
 5451  
 5461  
 5471  
 5481  
 5491  
 5501  
 5511  
 5521  
 5531  
 5541  
 5551  
 5561  
 5571  
 5581  
 5591  
 5601  
 5611  
 5621  
 5631  
 5641  
 5651  
 5661  
 5671  
 5681  
 5691  
 5701  
 5711  
 5721  
 5731  
 5741  
 5751  
 5761  
 5771  
 5781  
 5791  
 5801  
 5811  
 5821  
 5831  
 5841  
 5851  
 5861  
 5871  
 5881  
 5891  
 5901  
 5911  
 5921  
 5931  
 5941  
 5951  
 5961  
 5971  
 5981  
 5991  
 6001  
 6011  
 6021  
 6031  
 6041  
 6051  
 6061  
 6071  
 6081  
 6091  
 6101  
 6111  
 6121  
 6131  
 6141  
 6151  
 6161  
 6171  
 6181  
 6191  
 6201  
 6211  
 6221  
 6231  
 6241  
 6251  
 6261  
 6271  
 6281  
 6291  
 6301  
 6311  
 6321  
 6331  
 6341  
 6351  
 6361  
 6371  
 6381  
 6391  
 6401  
 6411  
 6421  
 6431  
 6441  
 6451  
 6461  
 6471  
 6481  
 6491  
 6501  
 6511  
 6521  
 6531  
 6541  
 6551  
 6561  
 6571  
 6581  
 6591  
 6601  
 6611  
 6621  
 6631  
 6641  
 6651  
 6661  
 6671  
 6681  
 6691  
 6701  
 6711  
 6721  
 6731  
 6741  
 6751  
 6761  
 6771  
 6781  
 6791  
 6801  
 6811  
 6821  
 6831  
 6841  
 6851  
 6861  
 6871  
 6881  
 6891  
 6901  
 6911  
 6921  
 6931  
 6941  
 6951  
 6961  
 6971  
 6981  
 6991  
 7001  
 7011  
 7021  
 7031  
 7041  
 7051  
 7061  
 7071  
 7081  
 7091  
 7101  
 7111  
 7121  
 7131  
 7141  
 7151  
 7161  
 7171  
 7181  
 7191  
 7201  
 7211  
 7221  
 7231  
 7241  
 7251  
 7261  
 7271  
 7281  
 7291  
 7301  
 7311  
 7321  
 7331  
 7341  
 7351  
 7361  
 7371  
 7381  
 7391  
 7401  
 7411  
 7421  
 7431  
 7441  
 7451  
 7461  
 7471  
 7481  
 7491  
 7501  
 7511  
 7521  
 7531  
 7541  
 7551  
 7561  
 7571  
 7581  
 7591  
 7601  
 7611  
 7621  
 7631  
 7641  
 7651  
 7661  
 7671  
 7681  
 7691  
 7701  
 7711  
 7721  
 7731  
 7741  
 7751  
 7761  
 7771  
 7781  
 7791  
 7801  
 7811  
 7821  
 7831  
 7841  
 7851  
 7861  
 7871  
 7881  
 7891  
 7901  
 7911  
 7921  
 7931  
 7941  
 7951  
 7961  
 7971  
 7981  
 7991  
 8001  
 8011  
 8021  
 8031  
 8041  
 8051  
 8061  
 8071  
 8081  
 8091  
 8101  
 8111  
 8121  
 8131  
 8141  
 8151  
 8161  
 8171  
 8181  
 8191  
 8201  
 8211  
 8221  
 8231  
 8241  
 8251  
 8261  
 8271  
 8281  
 8291  
 8301  
 8311  
 8321  
 8331  
 8341  
 8351  
 8361  
 8371  
 8381  
 8391  
 8401  
 8411  
 8421  
 8431  
 8441  
 8451  
 8461  
 8471  
 8481  
 8491  
 8501  
 8511  
 8521  
 8531  
 8541  
 8551  
 8561  
 8571  
 8581  
 8591  
 8601  
 8611  
 8621  
 8631  
 8641  
 8651  
 8661  
 8671  
 8681  
 8691  
 8701  
 8711  
 8721  
 8731  
 8741  
 8751  
 8761  
 8771  
 8781  
 8791  
 8801  
 8811  
 8821  
 8831  
 8841  
 8851  
 8861  
 8871  
 8881  
 8891  
 8901  
 8911  
 8921  
 8931  
 8941  
 8951  
 8961  
 8971  
 8981  
 8991  
 9001  
 9011  
 9021  
 9031  
 9041  
 9051  
 9061  
 9071  
 9081  
 9091  
 9101  
 9111  
 9121  
 9131  
 9141  
 9151  
 9161  
 9171  
 9181  
 9191  
 9201  
 9211  
 9221  
 9231  
 9241  
 9251  
 9261  
 9271  
 9281  
 9291  
 9301  
 9311  
 9321  
 9331  
 9341  
 9351  
 9361  
 9371  
 9381  
 9391  
 9401  
 9411  
 9421  
 9431  
 9441  
 9451  
 9461  
 9471  
 9481  
 9491  
 9501  
 9511  
 9521  
 9531  
 9541  
 9551  
 9561  
 9571  
 9581  
 9591  
 9601  
 9611  
 9621  
 9631  
 9641  
 9651  
 9661  
 9671  
 9681  
 9691  
 9701  
 9711  
 9721  
 9731  
 9741  
 9751  
 9761  
 9771  
 9781  
 9791  
 9801  
 9811  
 9821  
 9831  
 9841  
 9851  
 9861  
 9871  
 9881  
 9891  
 9901  
 9911  
 9921  
 9931  
 9941  
 9951  
 9961  
 9971  
 9981  
 9991  
 10001  
 10011  
 10021  
 10031  
 10041  
 10051  
 10061  
 10071  
 10081  
 10091  
 10101  
 10111  
 10121  
 10131  
 10141  
 10151  
 10161  
 10171  
 10181  
 10191  
 10201  
 10211  
 10221  
 10231  
 10241  
 10251  
 10261  
 10271  
 10281  
 10291  
 10301  
 10311  
 10321  
 10331  
 10341  
 10351  
 10361  
 10371  
 10381  
 10391  
 10401  
 10411  
 10421  
 10431  
 10441  
 10451  
 10461  
 10471  
 10481  
 10491  
 10501  
 10511  
 10521  
 10531  
 10541  
 10551  
 10561  
 10571  
 10581  
 10591  
 10601  
 10611  
 10621  
 10631  
 10641  
 10651  
 10661  
 10671  
 10681  
 10691  
 10701  
 10711  
 10721  
 10731  
 10741  
 10751  
 10761  
 10771  
 10781  
 10791  
 10801  
 10811  
 10821  
 10831  
 10841  
 10851  
 10861  
 10871  
 10881  
 10891  
 10901  
 10911  
 10921  
 10931  
 10941  
 10951  
 10961  
 10971  
 10981  
 10991  
 11001  
 11011  
 11021  
 11031  
 11041  
 11051  
 11061  
 11071  
 11081  
 11091  
 11101  
 11111  
 11121  
 11131  
 11141  
 11151  
 11161  
 11171  
 11181  
 11191  
 11201  
 11211  
 11221  
 11231  
 11241  
 11251  
 11261  
 11271  
 11281  
 11291  
 11301  
 11311  
 11321  
 11331  
 11341  
 11351  
 11361  
 11371  
 11381  
 11391  
 11401  
 11411  
 11421  
 11431  
 11441  
 11451  
 11461  
 11471  
 11481  
 11491  
 11501  
 11511  
 11521  
 11531  
 11541  
 11551  
 11561  
 11571  
 11581  
 11591  
 11601  
 11611  
 11621  
 11631  
 11641  
 11651  
 11661  
 11671  
 11681  
 11691  
 11701  
 11711  
 11721  
 11731  
 11741  
 11751  
 11761  
 11771  
 11781  
 11791  
 11801  
 11811  
 11821  
 11831  
 11841  
 11851  
 11861  
 11871  
 11881  
 11891  
 11901  
 11911  
 11921  
 11931  
 11941  
 11951  
 11961  
 11971  
 11981  
 11991  
 12001  
 12011  
 12021  
 12031  
 12041  
 12051  
 12061  
 12071  
 12081  
 12091  
 12101  
 12111  
 12121  
 12131  
 12141  
 12151  
 12161  
 12171  
 12181  
 12191  
 12201  
 12211  
 12221  
 12231  
 12241  
 12251  
 12261  
 12271  
 12281  
 12291  
 12301  
 12311  
 12321  
 12331  
 12341  
 12351  
 12361  
 12371  
 12381  
 12391  
 12401  
 12411  
 12421  
 12431  
 12441  
 12451  
 12461  
 12471  
 12481  
 12491  
 12501  
 12511  
 12521  
 12531  
 12541  
 12551  
 12561  
 12571  
 12581  
 12591  
 12601  
 12611  
 12621  
 12631  
 12641  
 12651  
 12661  
 12671  
 12681  
 12691  
 12701  
 12711  
 12721  
 12731  
 12741  
 12751  
 12761  
 12771  
 12781  
 12791  
 12801  
 12811  
 12821  
 12831  
 12841  
 12851  
 12861  
 12871  
 12881  
 12891  
 12901  
 12911  
 12921  
 12931  
 12941  
 12951  
 12961  
 12971  
 12981  
 12991  
 13001  
 13011  
 13021  
 13031  
 13041  
 13051  
 13061  
 13071  
 13081  
 13091  
 13101  
 13111  
 13121  
 13131  
 13141  
 13151  
 13161  
 13171  
 13181  
 13191  
 13201  
 13211  
 13221  
 13231  
 13241  
 13251  
 13261  
 13271  
 13281  
 13291  
 13301  
 13311  
 13321  
 13331  
 13341  
 13351  
 13361  
 13371  
 13381  
 13391  
 13401  
 13411  
 13421  
 13431  
 13441  
 13451  
 13461  
 13471  
 13481  
 13491  
 13501  
 13511  
 13521  
 13531  
 13541  
 13551  
 13561  
 13571  
 13581  
 13591  
 13601  
 13611  
 13621  
 13631  
 13641  
 13651  
 13661  
 13671  
 13681  
 13691  
 13701  
 13711  
 13721  
 13731  
 13741  
 13751  
 13761  
 13771  
 13781  
 13791  
 13801  
 13811  
 13821  
 13831  
 13841  
 13851  
 13861  
 13871  
 13881  
 13891  
 13901  
 13911  
 13921  
 13931  
 13941






5  
FIGURE A

FIG. 5

37/39

## Variable Heavy Domain

	10	20	30	40
2C4	EVQLQQSGPELVKPGT	SVKISCKAS	[GFTFIDYIMD]	WVKQS
	** ** *	* ** *		**
574	EVQLVESGGGLVQPGG	SLRLSCAAS	[GFTFTDYTMD]	WVRQA
			** *	
hum III	EVQLVESGGGLVQPGG	SLRLSCAAS	[GFTFSSYAMS]	WVRQA

	50 a	60	70	80
2C4	HGKSLEWIG	[DVNPNSGGSIYNQRPKG]	KASLTVDRSSRIVYM	
	* * *		*** *	**** *
574	PGKGLEWVA	[DVNPNSGGSIYNQRPKG]	RFTLSVDRSKNTLYL	
		***** ** *	* * *	
hum III	PGKGLEWVA	[VISGDGGSTYYADSVKG]	RFTISRDN SKNTLYL	

	abc	90	100ab	110
2C4	ELRSLTFEDTAVYYCAR	[NLGPSFYFDY]	WGQGTTLTVSS	
	*** **		**	
574	QMNSLRAEDTAVYYCAR	[NLGPSFYFDY]	WGQGTTLTVSS	
		*****		
hum III	QMNSLRAEDTAVYYCAR	[GRVGYSLYDY]	WGQGTTLTVSS	

FIG. 6

38/37

## Variable Light Domain

	10	20	30	40
2C4	DTVMTQSHKIMSTSVGDRVSITC	[KASQDV SIGVA]	WYQQRP	
	**      **** *	*	*	
574	DIQMTQSPSSLSASVGDRVTITC	[KASQDV SIGVA]	WYQQKP	
		*      ** ****		
hum κI	DIQMTQSPSSLSASVGDRVTITC	[RASQIS NYLA]	WYQQKP	
	50	60	70	80
2C4	GQSPKLLIY [SASYRYT]	GVPDRFTGSGSGTDFTFTISSVQA		
	**	* *	* *	
574	GKAPKLLIY [SASYRYT]	GVPSRFSGSGSGTDFTLTISLQP		
	* *****			
hum κI	GKAPKLLIY [AASSLES]	GVPSRFSGSGSGTDFTLTISLQP		
	90	100		
2C4	EDLAVYYC [QQYYIYPYT]	FGGGTKLEIKRT		
	* *	* *		
574	EDFATYYC [QQYYIYPYT]	FGQGTKVEIKRT		
	*** *			
hum κI	EDFATYYC [QQYNSLPWT]	FGQGTKVEIKRT		

FIG. 7

39/37

